649 results on '"Nguyen R"'
Search Results
202. Open data from the third observing run of LIGO, Virgo, KAGRA and GEO
- Author
-
The LIGO Scientific Collaboration, The Virgo Collaboration, The KAGRA Collaboration, Abbott, R., Abe, H., Acernese, F., Ackley, K., Adhicary, S., Adhikari, N., Adhikari, R. X., Adkins, V. K., Adya, V. B., Affeldt, C., Agarwal, D., Agathos, M., Aguiar, O. D., Aiello, L., Ain, A., Ajith, P., Akutsu, T., Albanesi, S., Alfaidi, R. A., Al-Jodah, A., Alléné, C., Allocca, A., Almualla, M., Altin, P. A., Amato, A., Amez-Droz, L., Amorosi, A., Anand, S., Ananyeva, A., Andersen, R., Anderson, S. B., Anderson, W. G., Andia, M., Ando, M., Andrade, T., Andres, N., Andrés-Carcasona, M., Andrić, T., Ansoldi, S., Antelis, J. M., Antier, S., Aoumi, M., Apostolatos, T., Appavuravther, E. Z., Appert, S., Apple, S. K., Arai, K., Araya, A., Araya, M. C., Areeda, J. S., Arène, M., Aritomi, N., Arnaud, N., Arogeti, M., Aronson, S. M., Arun, K. G., Asada, H., Ashton, G., Aso, Y., Assiduo, M., Melo, S. Assis de Souza, Aston, S. M., Astone, P., Aubin, F., AultONeal, K., Babak, S., Badalyan, A., Badaracco, F., Badger, C., Bae, S., Bagnasco, S., Bai, Y., Baier, J. G., Baiotti, L., Baird, J., Bajpai, R., Baka, T., Ball, M., Ballardin, G., Ballmer, S. W., Baltus, G., Banagiri, S., Banerjee, B., Bankar, D., Baral, P., Barayoga, J. C., Barber, J., Barish, B. C., Barker, D., Barneo, P., Barone, F., Barr, B., Barsotti, L., Barsuglia, M., Barta, D., Barthelmy, S. D., Barton, M. A., Bartos, I., Basak, S., Basalaev, A., Bassiri, R., Basti, A., Bawaj, M., Bayley, J. C., Baylor, A. C., Bazzan, M., Bécsy, B., Bedakihale, V. M., Beirnaert, F., Bejger, M., Bell, A. S., Benedetto, V., Beniwal, D., Benoit, W., Bentley, J. D., Yaala, M. Ben, Bera, S., Berbel, M., Bergamin, F., Berger, B. K., Bernuzzi, S., Beroiz, M., Berry, C. P. L., Bersanetti, D., Bertolini, A., Betzwieser, J., Beveridge, D., Bevins, N., Bhandare, R., Bhandari, A. V., Bhardwaj, U., Bhatt, R., Bhattacharjee, D., Bhaumik, S., Bianchi, A., Bilenko, I. A., Bilicki, M., Billingsley, G., Bini, S., Birnholtz, O., Biscans, S., Bischi, M., Biscoveanu, S., Bisht, A., Biswas, B., Bitossi, M., Bizouard, M. -A., Blackburn, J. K., Blair, C. D., Blair, D. G., Blair, R. M., Bobba, F., Bode, N., Boër, M., Bogaert, G., Boileau, G., Boldrini, M., Bolingbroke, G. N., Bonavena, L. D., Bondarescu, R., Bondu, F., Bonilla, E., Bonilla, G. S., Bonnand, R., Booker, P., Bork, R., Boschi, V., Bose, N., Bose, S., Bossilkov, V., Boudart, V., Bouffanais, Y., Bozzi, A., Bradaschia, C., Brady, P. R., Braglia, M., Branch, A., Branchesi, M., Brau, J. E., Breschi, M., Briant, T., Brillet, A., Brinkmann, M., Brockill, P., Brooks, A. F., Brooks, J., Brown, D. D., Brunett, S., Bruno, G., Bruntz, R., Bryant, J., Bucci, F., Buchanan, J., Bulashenko, O., Bulik, T., Bulten, H. J., Buonanno, A., Burtnyk, K., Buscicchio, R., Buskulic, D., Buy, C., Byer, R. L., Davies, G. S. Cabourn, Cabras, G., Cabrita, R., Cadonati, L., Caesar, S., Cagnoli, G., Cahillane, C., Bustillo, J. Calderón, Callaghan, J. D., Callister, T. A., Calloni, E., Camp, J. B., Canepa, M., Santoro, G. Caneva, Cannavacciuolo, M., Cannon, K. C., Cao, H., Cao, Z., Capistran, L. A., Capocasa, E., Capote, E., Carapella, G., Carbognani, F., Carlassara, M., Carlin, J. B., Carpinelli, M., Carter, J. J., Carullo, G., Diaz, J. Casanueva, Casentini, C., Castaldi, G., Castro-Lucas, S. Y., Caudill, S., Cavaglià, M., Cavalieri, R., Cella, G., Cerdá-Durán, P., Cesarini, E., Chaibi, W., Chakalis, W., Subrahmanya, S. Chalathadka, Champion, E., Chan, C., Chan, C. L., Chandra, K., Chang, I. P., Chang, W., Chanial, P., Chao, S., Chapman-Bird, C., Charlton, E. L., Charlton, P., Chassande-Mottin, E., Chastain, L., Chatterjee, C., Chatterjee, Debarati, Chatterjee, Deep, Chaturvedi, M., Chaty, S., Chatziioannou, K., Chen, D., Chen, H., Chen, H. Y., Chen, J., Chen, K. H., Chen, X., Chen, Y. -R., Chen, Y., Cheng, H., Chessa, P., Cheung, H. Y., Chia, H. Y., Chiadini, F., Chiang, C-I., Chiang, C., Chiarini, G., Chiba, A., Chiba, R., Chierici, R., Chincarini, A., Chiofalo, M. L., Chiummo, A., Choudhary, S., Christensen, N., Chua, S. S. Y., Chung, K. W., Ciani, G., Ciecielag, P., Cieślar, M., Cifaldi, M., Ciobanu, A. A., Ciolfi, R., Clara, F., Clark, J. A., Clarke, T. A., Clearwater, P., Clesse, S., Cleva, F., Coccia, E., Codazzo, E., Cohadon, P. -F., Colleoni, M., Collette, C. G., Colombo, A., Colpi, M., Compton, C. M., Conti, L., Cooper, S. J., Corban, P., Corbitt, T. R., Cordero-Carrión, I., Corezzi, S., Cornish, N. J., Corsi, A., Cortese, S., Coschizza, A. C., Cottingham, R., Coughlin, M. W., Coulon, J. -P., Countryman, S. T., Coupechoux, J. -F., Cousins, B., Couvares, P., Coward, D. M., Cowart, M. J., Cowburn, B. D., Coyne, D. C., Coyne, R., Craig, K., Creighton, J. D. E., Creighton, T. D., Criswell, A. W., Crockett-Gray, J. C. G., Croquette, M., Crowder, S. G., Cudell, J. R., Cullen, T. J., Cumming, A., Cummings, R., Cuoco, E., Curyło, M., Dabadie, P., Canton, T. Dal, Dall'Osso, S., Dálya, G., D'Angelo, B., Danilishin, S., D'Antonio, S., Danzmann, K., Darroch, K. E., Darsow-Fromm, C., Dasgupta, A., Datrier, L. E. H., Datta, Sayantani, Dattilo, V., Dave, I., Davenport, A., Davier, M., Davis, D., Davis, M. C., Daw, E. J., Dax, M., DeBra, D., Deenadayalan, M., Degallaix, J., De Laurentis, M., Deléglise, S., Del Favero, V., De Lillo, F., De Lillo, N., Dell'Aquila, D., Del Pozzo, W., De Matteis, F., D'Emilio, V., Demos, N., Dent, T., Depasse, A., De Pietri, R., De Rosa, R., De Rossi, C., DeSalvo, R., De Simone, R., Dhurandhar, S., Diab, R., Diamond, P. Z., Díaz, M. C., Didio, N. A., Dietrich, T., Di Fiore, L., Di Fronzo, C., Di Giorgio, C., Di Giovanni, F., Di Giovanni, M., Di Girolamo, T., Diksha, D., Di Lieto, A., Di Michele, A., Di Pace, S., Di Palma, I., Di Renzo, F., Divyajyoti, Dmitriev, A., Doctor, Z., Dohmen, E., Doleva, P. P., Donahue, L., D'Onofrio, L., Donovan, F., Dooley, K. L., Dooney, T., Doravari, S., Dorosh, O., Drago, M., Driggers, J. C., Drori, Y., Ducoin, J. -G., Dunn, L., Dupletsa, U., Durante, O., D'Urso, D., Duverne, P. -A., Dwyer, S. E., Eassa, C., Easter, P. J., Ebersold, M., Eckhardt, T., Eddolls, G., Edelman, B., Edo, T. B., Edy, O., Effler, A., Eichholz, J., Eisenmann, M., Eisenstein, R. A., Ejlli, A., Engelby, E., Engl, A. J., Errico, L., Essick, R. C., Estellés, H., Estevez, D., Etzel, T., Evans, C., Evans, M., Evans, T. M., Evstafyeva, T., Ewing, B. E., Fabrizi, F., Faedi, F., Fafone, V., Fair, H., Fairhurst, S., Fan, P. C., Fan, X., Farah, A. M., Farr, B., Farr, W. M., Fauchon-Jones, E. J., Favaro, G., Favata, M., Fays, M., Feicht, J., Fejer, M. M., Fenyvesi, E., Ferguson, D. L., Fernandez-Galiana, A., Ferrante, I., Ferreira, T. A., Fidecaro, F., Figura, P., Fiori, A., Fiori, I., Fishbach, M., Fisher, R. P., Fittipaldi, R., Fiumara, V., Flaminio, R., Fleischer, S. M., Fleming, L. S., Floden, E., Fong, H. K., Font, J. A., Fornal, B., Forsyth, P. W. F., Franke, A., Frasca, S., Frasconi, F., Freed, J. P., Frei, Z., Freise, A., Freitas, O., Frey, R., Fritschel, P., Frolov, V. V., Fronzé, G. G., Fujimoto, Y., Fukunaga, I., Fulda, P., Fyffe, M., Gabbard, H. A., Gabella, W. E., Gadre, B. U., Gaglani, K., Gair, J. R., Gais, J., Galaudage, S., Gallardo, S., Gamba, R., Ganapathy, D., Ganguly, A., Gao, D., Gaonkar, S. G., Garaventa, B., Garcia-Bellido, J., García-Núñez, C., García-Quirós, C., Gardner, K. A., Gargiulo, J., Garufi, F., Gasbarra, C., Gateley, B., Gayathri, V., Gemme, G., Gennai, A., George, J., Gerberding, O., Gergely, L., Ghonge, S., Ghosh, Abhirup, Ghosh, Archisman, Ghosh, Shaon, Ghosh, Shrobana, Ghosh, Tathagata, Giacoppo, L., Giaime, J. A., Giardina, K. D., Gibson, D. R., Gier, C., Giri, P., Gissi, F., Gkaitatzis, S., Glanzer, J., Gleckl, A. E., Glotin, F., Godfrey, J., Godwin, P., Goetz, E., Goetz, R., Golomb, J., Goncharov, B., González, G., Gosselin, M., Gouaty, R., Gould, D. W., Goyal, S., Grace, B., Grado, A., Graham, V., Granata, M., Granata, V., Gras, S., Grassia, P., Gray, C., Gray, R., Greco, G., Green, A. C., Green, R., Green, S., Green, S. R., Gretarsson, A. M., Gretarsson, E. M., Griffith, D., Griffiths, W. L., Griggs, H. L., Grignani, G., Grimaldi, A., Grote, H., Gruson, A. S., Guerra, D., Guetta, D., Guidi, G. M., Guimaraes, A. R., Gulati, H. K., Gulminelli, F., Gunny, A. M., Guo, H., Guo, Y., Gupta, Anchal, Gupta, Anuradha, Gupta, Ish, Gupta, N. C., Gupta, P., Gupta, S. K., Gurs, J., Gushima, Y., Gustafson, E. K., Gutierrez, N., Guzman, F., Haegel, L., Hain, G., Haino, S., Halim, O., Hall, E. D., Hamilton, E. Z., Hammond, G., Han, W. -B., Haney, M., Hanks, J., Hanna, C., Hannam, M. D., Hannuksela, O. A., Hansen, H., Hanson, J., Harada, R., Harder, T., Haris, K., Harmark, T., Harms, J., Harry, G. M., Harry, I. W., Hartwig, D., Haskell, B., Haster, C. -J., Hathaway, J. S., Haughian, K., Hayakawa, H., Hayama, K., Hayes, F. J., Healy, J., Heffernan, A., Heidmann, A., Heintze, M. C., Heinze, J., Heinzel, J., Heitmann, H., Hellman, F., Hello, P., Helmling-Cornell, A. F., Hemming, G., Hendry, M., Heng, I. S., Hennes, E., Hennig, J. -S., Hennig, M., Henshaw, C., Vivanco, F. Hernandez, Heurs, M., Hewitt, A. L., Higginbotham, S., Hild, S., Hill, P., Himemoto, Y., Hines, A. S., Hirata, N., Hirose, C., Ho, J., Hochheim, S., Hofman, D., Hohmann, J. N., Holcomb, D. G., Holland, N. A., Holley-Bockelmann, K., Hollows, I. J., Holmes, Z. J., Holt, K., Holz, D. E., Hong, Q., Hornung, J., Hoshino, S., Hough, J., Hourihane, S., Howell, D., Howell, E. J., Hoy, C. G., Hoyland, D., Hsieh, B. -H., Hsieh, H. -F., Hsiung, C., Hsu, H., Hu, P., Hu, Q., Huang, H. -Y., Huang, Y. -J., Huang, Y., Huang, Y. T., Hübner, M. T., Huddart, A. D., Hughey, B., Hui, D. C. Y., Hui, V., Husa, S., Huttner, S. H., Huxford, R., Huynh-Dinh, T., Hyland, J., Iakovlev, A., Iandolo, G. A., Idzkowski, B., Iess, A., Inayoshi, K., Inoue, Y., Iorio, G., Iosif, P., Irwin, J., Isi, M., Ismail, M. A., Itoh, Y., Iyer, B. R., JaberianHamedan, V., Jacqmin, T., Jacquet, P. -E., Jadhav, S. J., Jadhav, S. P., Jain, D., Jain, T., James, A. L., Jan, A. Z., Jani, K., Janiurek, L., Janquart, J., Janssens, K., Janthalur, N. N., Jaraba, S., Jaranowski, P., Jarov, S., Jasal, P., Jaume, R., Javed, W., Jenkins, A. C., Jenner, K., Jennings, A., Jia, W., Jiang, J., Liu, Jian, Jin, H. -B., Johansmeyer, K., Johns, G. R., Johnson, N. A., Johnston, R., Johny, N., Jones, A. W., Jones, D. H., Jones, D. I., Jones, P., Jones, R., Joshi, P., Ju, L., Jung, K., Junker, J., Juste, V., Kajita, T., Kalaghatgi, C., Kalogera, V., Kamai, B., Kamiizumi, M., Kanda, N., Kandhasamy, S., Kang, G., Kanner, J. B., Kapadia, S. J., Kapasi, D. P., Karat, S., Karathanasis, C., Karki, S., Kasamatsu, D., Kas-danouche, Y. A., Kashyap, R., Kasprzack, M., Kastaun, W., Kato, J., Katsanevas, S., Katsavounidis, E., Katsuren, J. K., Katzman, W., Kaur, T., Kawabe, K., Kawazoe, K., Kéfélian, F., Keitel, D., Kellard, I., Kelley-Derzon, J., Kennington, J., Key, J. S., Khadka, S., Khalili, F. Y., Khan, S., Khanam, T., Khazanov, E. A., Khursheed, M., Kijbunchoo, N., Kim, C., Kim, J. C., Kim, K., Kim, M. H., Kim, P., Kim, S., Kim, W. S., Kim, Y. -M., Kimball, C., Kimura, N., Kinley-Hanlon, M., Kirchhoff, R., Kissel, J. S., Kiyota, T., Klimenko, S., Klinger, T., Knee, A. M., Knust, N., Kobayashi, Y., Koch, P., Koehlenbeck, S. M., Koekoek, G., Kohri, K., Kokeyama, K., Koley, S., Koliadko, N. D., Kolitsidou, P., Kolstein, M., Kondrashov, V., Kong, A. K. H., Kontos, A., Korobko, M., Kossak, R. V., Kouvatsos, N., Kovalam, M., Koyama, N., Kozak, D. B., Kranzhoff, L., Kranzhoff, S. L., Kringel, V., Krishnendu, N. V., Królak, A., Kuehn, G., Kuijer, P., Kukihara, M., Kulkarni, S., Kumar, A., Kumar, Praveen, Kumar, Prayush, Kumar, Rahul, Kumar, Rakesh, Kume, J., Kuns, K., Kuroyanagi, S., Kuwahara, S., Kwak, K., Lacaille, G., Lagabbe, P., Laghi, D., Lakkis, M. H., Lalande, E., Lalleman, M., Lamberts, A., Landry, M., Lane, B. B., Lang, R. N., Lange, J., Lantz, B., La Rana, A., La Rosa, I., Lartaux-Vollard, A., Lasky, P. D., Lawrence, J., Laxen, M., Lazzarini, A., Lazzaro, C., Leaci, P., Leavey, S., LeBohec, S., Lecoeuche, Y. K., Lee, E., Lee, H. M., Lee, H. W., Lee, K., Lee, R. -L., Lee, R., Lee, S., Legred, I. N., Lehmann, J., Lehner, L., Lemaître, A., Lenti, M., Leonardi, M., Leonova, E., Leroy, N., Letendre, N., Lethuillier, M., Levesque, C., Levin, Y., Leyde, K., Li, A. K. Y., Li, K. L., Li, T. G. F., Li, X., Lin, C. -Y., Lin, E. T., Lin, F-K., Lin, F-L., Lin, F., Lin, H. L., Lin, H., Lin, L. C. -C., Linde, F., Linker, S. D., Littenberg, T. B., Liu, A., Liu, G. C., Llamas, F., Lo, R. K. L., Lo, T., London, L. T., Longo, A., Lopez, D., Portilla, M. Lopez, Lorenzini, M., Loriette, V., Lormand, M., Losurdo, G., Lott, T. P., Lough, J. D., Loughlin, H. A., Lousto, C. O., Lovelace, G., Lowry, M. J., Lück, H., Lumaca, D., Lundgren, A. P., Lung, Y., Lussier, A. W., Lynam, J. E., Ma, L., Ma, S., Ma'arif, M., Macas, R., MacInnis, M., Macleod, D. M., MacMillan, I. A. O., Macquet, A., Hernandez, I. Magaña, Magazzù, C., Magee, R. M., Maggiore, R., Magnozzi, M., Mahesh, M., Mahesh, S., Maini, M., Majorana, E., Makarem, C. N., Maliakal, S., Malik, A., Man, N., Mandic, V., Mangano, V., Mannix, B., Mansell, G. L., Mansingh, G., Manske, M., Mantovani, M., Mapelli, M., Marchesoni, F., Pina, D. Marín, Marion, F., Márka, S., Márka, Z., Markakis, C., Markosyan, A. S., Markowitz, A., Maros, E., Marquina, A., Marsat, S., Martelli, F., Martin, I. W., Martin, R. M., Martinez, B. B., Martinez, M., Martinez, V. A., Martinez, V., Martinovic, K., Martynov, D. V., Marx, E. J., Masalehdan, H., Mason, K., Masserot, A., Reid, M. Masso, Mastrodicasa, M., Mastrogiovanni, S., Mateu-Lucena, M., Matiushechkina, M., Matsunaga, K., Mavalvala, N., McCarthy, R., McClelland, D. E., McClincy, P. K., McCormick, S., McCuller, L., McGhee, G. I., McGinn, J., McIsaac, C., McIver, J., McLeod, A., McRae, T., McWilliams, S. T., Meacher, D., Mehmet, M., Mehta, A. K., Meijer, Q., Melatos, A., Mendell, G., Menendez-Vazquez, A., Menoni, C. S., Mercer, R. A., Mereni, L., Merfeld, K., Merilh, E. L., Merritt, J. D., Merzougui, M., Messenger, C., Messick, C., Meyers, P. M., Meylahn, F., Mhaske, A., Miani, A., Miao, H., Michaloliakos, I., Michel, C., Michimura, Y., Middleton, H., Mihaylov, D. P., Miller, A., Miller, A. L., Miller, B., Miller, S., Millhouse, M., Mills, J. C., Milotti, E., Minenkov, Y., Mio, N., Mir, Ll. M., Miravet-Tenés, M., Mishra, A., Mishra, C., Mishra, T., Mistry, T., Mitchell, A. L., Mitra, S., Mitrofanov, V. P., Mitselmakher, G., Mittleman, R., Miyakawa, O., Miyoki, S., Mo, Geoffrey, Modafferi, L. M., Moguel, E., Mohapatra, S. R. P., Mohite, S. R., Molina-Ruiz, M., Mondal, C., Mondin, M., Montani, M., Moore, C. J., Moragues, J., Moraru, D., Morawski, F., More, A., More, S., Moreno, C., Moreno, G., Morisaki, S., Moriwaki, Y., Morras, G., Moscatello, A., Mours, B., Mow-Lowry, C. M., Mozzon, S., Muciaccia, F., Mukherjee, D., Mukherjee, Soma, Mukherjee, Subroto, Mukherjee, Suvodip, Mukund, N., Mullavey, A., Munch, J., Muñiz, E. A., Murray, P. G., Murray-Dean, J., Muusse, S., Nadji, S. L., Nagar, A., Nagar, T., Nagarajan, N., Nakamura, K., Nakano, H., Nakano, M., Nakayama, Y., Napolano, V., Nardecchia, I., Narikawa, T., Narola, H., Naticchioni, L., Nayak, R. K., Neil, B. F., Neilson, J., Nelson, A., Nelson, T. J. N., Nery, M., Nesseris, S., Neunzert, A., Ng, K. Y., Ng, S. W. S., Nguyen, C., Nguyen, P., Nguyen, R., Nguyen, T., Quynh, L. Nguyen, Nichols, S. A., Nieradka, G., Nishino, Y., Nishizawa, A., Nissanke, S., Nitoglia, E., Niu, W., Nocera, F., Norman, M., North, C., Novak, J., Siles, J. F. Nuño, Nurbek, G., Nuttall, L. K., Oberling, J., O'Dell, J., Oelker, E., Oertel, M., Oganesyan, G., Oh, J. J., Oh, K., Oh, S. H., O'Hanlon, T., Ohashi, M., Ohashi, T., Ohkawa, M., Ohme, F., Ohta, H., Oliveira, A. S., Oliveri, R., Oohara, K., O'Reilly, B., Ormiston, R. G., Ormsby, N. D., Orselli, M., O'Shaughnessy, R., O'Shea, E., Oshima, Y., Oshino, S., Ossokine, S., Osthelder, C., Ottaway, D. J., Overmier, H., Pace, A. E., Pagano, R., Page, M. A., Pai, A., Pai, S. A., Pal, S., Palashov, O., Pálfi, M., Palomba, C., Pan, K. C., Panda, P. K., Pang, P. T. H., Pannarale, F., Pant, B. C., Panther, F. H., Paoletti, F., Paoli, A., Paolone, A., Papalexakis, E. E., Pappas, G., Parisi, A., Park, J., Parker, W., Pascucci, D., Pasqualetti, A., Passaquieti, R., Passuello, D., Patel, M., Pathak, M., Patra, A., Patricelli, B., Patron, A. S., Paul, S., Payne, E., Pearce, T., Pedraza, M., Pedurand, R., Pegna, R., Pegoraro, M., Pele, A., Arellano, F. E. Peña, Penn, S., Perego, A., Pereira, A., Perez, C. J., Périgois, C., Perkins, C. C., Perreca, A., Perriès, S., Perry, J. W., Pesios, D., Petermann, J., Petrillo, C., Pfeiffer, H. P., Pham, H., Pham, K. A., Phukon, K. S., Phurailatpam, H., Piccinni, O. J., Pichot, M., Piendibene, M., Piergiovanni, F., Pierini, L., Pierra, G., Pierro, V., Pillant, G., Pillas, M., Pilo, F., Pinard, L., Pineda-Bosque, C., Pinto, I. M., Piotrzkowski, B. J., Piotrzkowski, K., Pirello, M., Pitkin, M. D., Placidi, A., Placidi, E., Planas, M. L., Plastino, W., Poggiani, R., Polini, E., Pompili, L., Pong, D. Y. T., Ponrathnam, S., Porcelli, E., Portell, J., Porter, E. K., Posnansky, C., Poulton, R., Powell, Jade, Powell, Jonathan, Pracchia, M., Pradier, T., Prajapati, A. K., Prasai, K., Prasanna, R., Pratten, G., Principe, M., Prodi, G. A., Prokhorov, L., Prosposito, P., Prudenzi, L., Puecher, A., Pullin, J., Punturo, M., Puosi, F., Puppo, P., Pürrer, M., Qi, H., Quetschke, V., Quinonez, P. J., Quitzow-James, R., Raab, F. J., Raaijmakers, G., Radulesco, N., Raffai, P., Rail, S. X., Raja, S., Rajan, C., Ramirez, K. E., Ramirez, T. D., Ramos-Buades, A., Rana, D., Rana, J., Randel, E., Rangnekar, P. R., Rapagnani, P., Ray, A., Raymond, V., Raza, N., Razzano, M., Read, J., Regimbau, T., Rei, L., Reid, S., Reid, S. W., Reitze, D. H., Relton, P., Renzini, A., Rettegno, P., Revenu, B., Reza, A., Rezac, M., Rezaei, A. S., Ricci, F., Richards, D., Richardson, J. W., Rijal, A., Riles, K., Riley, H. K., Rinaldi, S., Robertson, C., Robertson, N. A., Robinet, F., Rocchi, A., Rodriguez, S., Rolland, L., Rollins, J. G., Romanelli, M., Romano, R., Romel, C. L., Romero, A., Romero-Shaw, I. M., Romie, J. H., Ronchini, S., Roocke, T. J., Rosa, L., Rosauer, T. J., Rose, C. A., Rosińska, D., Ross, M. P., Rossello, M., Roussel, A., Rowan, S., Rowlinson, S. J., Roy, S., Royzman, A., Rozza, D., Ruggi, P., Morales, E. Ruiz, Ruiz-Rocha, K., Ryan, K., Sachdev, S., Sadecki, T., Sadiq, J., Saffarieh, P., Saha, S. S., Saha, S., Saito, Y., Sakai, K., Sakellariadou, M., Sako, T., Sakon, S., Salafia, O. S., Salces-Carcoba, F., Salconi, L., Saleem, M., Salemi, F., Sallé, M., Samajdar, A., Sanchez, E. J., Sanchez, J. H., Sanchez, L. E., Sanchis-Gual, N., Sanders, J. R., Sanuy, A., Saravanan, T. R., Sarin, N., Sasli, A., Sassi, P., Sassolas, B., Satari, H., Sauter, O., Savage, R. L., Savant, V., Sawada, T., Sawant, H. L., Sayah, S., Schaetzl, D., Scheel, M., Scherf, S. J., Scheuer, J., Schiworski, M. G., Schmidt, P., Schmidt, S., Schmitz, S. J., Schnabel, R., Schneewind, M., Schofield, R. M. S., Schönbeck, A., Schuler, H., Schulte, B. W., Schutz, B. F., Schwartz, E., Scott, J., Scott, S. M., Seetharamu, T. C., Seglar-Arroyo, M., Sekiguchi, Y., Sellers, D., Sengupta, A. S., Sentenac, D., Seo, E. G., Sequino, V., Sergeev, A., Servignat, G., Setyawati, Y., Shaffer, T., Shahriar, M. S., Shaikh, M. A., Shams, B., Shao, L., Sharma, P., Chaudhary, S. Sharma, Shawhan, P., Shcheblanov, N. S., Sheela, A., Shen, B., Shepard, K. G., Sheridan, E., Shikano, Y., Shikauchi, M., Shimizu, H., Shimode, K., Shinkai, H., Shoemaker, D. H., Shoemaker, D. M., ShyamSundar, S., Sider, A., Siegel, H., Sieniawska, M., Sigg, D., Silenzi, L., Singer, L. P., Singh, D., Singh, M. K., Singh, N., Singha, A., Sintes, A. M., Sipala, V., Skliris, V., Slagmolen, B. J. J., Slaven-Blair, T. J., Smetana, J., Smith, J. R., Smith, L., Smith, R. J. E., Soldateschi, J., Somala, S. N., Somiya, K., Soni, K., Soni, S., Sordini, V., Sorrentino, F., Sorrentino, N., Sotani, H., Soulard, R., Souradeep, T., Sowell, E., Spagnuolo, V., Spencer, A. P., Spera, M., Spinicelli, P., Srivastava, A. K., Srivastava, V., Stachie, C., Stachurski, F., Steer, D. A., Steinlechner, J., Steinlechner, S., Stergioulas, N., StPierre, M., Strang, L. C., Stratta, G., Strong, M. D., Strunk, A., Sturani, R., Stuver, A. L., Suchenek, M., Sudhagar, S., Sueltmann, N., Sugiyama, T., Suh, H. G., Sullivan, A. G., Summerscales, T. Z., Sun, L., Sunil, S., Sur, A., Suresh, J., Sutton, P. J., Suzuki, Takamasa, Suzuki, Takanori, Swinkels, B. L., Syx, A., Szczepańczyk, M. J., Szewczyk, P., Tacca, M., Tagoshi, H., Tait, S. C., Takahashi, H., Takahashi, R., Takamori, A., Takano, S., Takeda, H., Takeda, M., Talbot, C. J., Talbot, C., Tamaki, M., Tamanini, N., Tanabe, D., Tanaka, K., Tanaka, T., Tanasijczuk, A. J., Tanioka, S., Tanner, D. B., Tao, D., Tao, L., Tapia, R. D., Martín, E. N. Tapia San, Tarafder, R., Taranto, C., Taruya, A., Tasson, J. D., Teloi, M., Tenorio, R., Terhune, J. E. S., Terkowski, L., Themann, H., Thirugnanasambandam, M. P., Thomas, L. M., Thomas, M., Thomas, P., Thomas, S., Thompson, J. E., Thondapu, S. R., Thorne, K. A., Thrane, E., Tiwari, Shubhanshu, Tiwari, Srishti, Tiwari, V., Toivonen, A. M., Tolley, A. E., Tomaru, T., Tomita, K., Tomura, T., Tonelli, M., Torres-Forné, A., Torrie, C. I., Melo, I. Tosta e, Tournefier, E., Trapananti, A., Travasso, F., Traylor, G., Trenado, J., Trevor, M., Tringali, M. C., Tripathee, A., Troiano, L., Trovato, A., Trozzo, L., Trudeau, R. J., Tsang, K. W., Tsang, T., Tse, M., Tso, R., Tsuchida, S., Tsukada, L., Tsutsui, T., Turbang, K., Turconi, M., Turski, C., Tuyenbayev, D., Ubach, H., Ubhi, A. S., Uchikata, N., Uchiyama, T., Udall, R. P., Uehara, T., Ueno, K., Unnikrishnan, C. S., Ushiba, T., Utina, A., Vahlbruch, H., Vaidya, N., Vajente, G., Vajpeyi, A., Valdes, G., Valentini, M., Vallero, S., Valsan, V., van Bakel, N., van Beuzekom, M., van Dael, M., Brand, J. F. J. van den, Broeck, C. Van Den, Vander-Hyde, D. C., van der Sluys, M., Van de Walle, A., van Dongen, J., van Haevermaet, H., van Heijningen, J. V., Vanosky, J., van Putten, M. H. P. M., van Ranst, Z., van Remortel, N., Vardaro, M., Vargas, A. F., Varma, V., Vasúth, M., Vecchio, A., Vedovato, G., Veitch, J., Veitch, P. J., Venneberg, J., Venugopalan, G., Verdier, P., Verkindt, D., Verma, P., Verma, Y., Vermeulen, S. M., Veske, D., Vetrano, F., Viceré, A., Vidyant, S., Viets, A. D., Vijaykumar, A., Villa-Ortega, V., Vina, M., Vincent, E. T., Vinet, J. -Y., Viret, S., Virtuoso, A., Vitale, S., Vocca, H., Voigt, D., von Reis, E. R. G., von Wrangel, J. S. A., Vorvick, C., Vyatchanin, S. P., Wade, L. E., Wade, M., Wagner, K. J., Walet, R. C., Walker, M., Wallace, G. S., Wallace, L., Wang, H., Wang, J. Z., Wang, W. H., Ward, R. L., Warner, J., Was, M., Washimi, T., Washington, N. Y., Watada, K., Watarai, D., Watchi, J., Wayt, K. E., Weaver, B., Weaving, C. R., Webster, S. A., Weinert, M., Weinstein, A. J., Weiss, R., Weller, C. M., Weller, R. A., Wellmann, F., Wen, L., Weßels, P., Wette, K., Whelan, J. T., White, D. D., Whiting, B. F., Whittle, C., Wilk, O. S., Wilken, D., Willetts, K., Williams, D., Williams, M. J., Williamson, A. R., Willis, J. L., Willke, B., Wipf, C. C., Woan, G., Woehler, J., Wofford, J. K., Wong, D., Wong, H. T., Wong, I. C. F., Wright, M., Wu, C., Wu, D. S., Wu, H., Wysocki, D. M., Xiao, L., Xu, V. A., Yadav, N., Yamada, T., Yamamoto, H., Yamamoto, K., Yamamoto, M., Yamamoto, T., Yamamoto, T. S., Yamashita, K., Yamazaki, R., Yang, F. W., Yang, K. Z., Yang, Y. -C., Yap, M. J., Yeeles, D. W., Yelikar, A. B., Yeung, T. Y., Yokoyama, J., Yokozawa, T., Yoo, J., Yu, Hang, Yu, Haocun, Yuzurihara, H., Zadrożny, A., Zannelli, A. J., Zanolin, M., Zeeshan, M., Zeidler, S., Zelenova, T., Zendri, J. -P., Zevin, M., Zhang, J., Zhang, L., Zhang, R., Zhang, T., Zhang, Y., Zhao, C., Zhao, Yue, Zhao, Yuhang, Zheng, Y., Zhong, H., Zhou, R., Zhu, X. J., Zhu, Z. -H., Zimmerman, A. B., Zucker, M. E., and Zweizig, J.
- Subjects
FOS: Physical sciences ,General Relativity and Quantum Cosmology (gr-qc) ,General Relativity and Quantum Cosmology - Abstract
The global network of gravitational-wave observatories now includes five detectors, namely LIGO Hanford, LIGO Livingston, Virgo, KAGRA, and GEO 600. These detectors collected data during their third observing run, O3, composed of three phases: O3a starting in April of 2019 and lasting six months, O3b starting in November of 2019 and lasting five months, and O3GK starting in April of 2020 and lasting 2 weeks. In this paper we describe these data and various other science products that can be freely accessed through the Gravitational Wave Open Science Center at https://gwosc.org. The main dataset, consisting of the gravitational-wave strain time series that contains the astrophysical signals, is released together with supporting data useful for their analysis and documentation, tutorials, as well as analysis software packages., 27 pages, 3 figures
203. Seasonal Abundance and Temperature Sensitivity of Sugarcane Delphacid (Homoptera: Delphacidae)1
- Author
-
Sosa, O., primary, Cherry, R. H., additional, and Nguyen, R., additional
- Published
- 1986
- Full Text
- View/download PDF
204. Threshold voltage drift of InPn‐channel enhancement mode metal‐insulator‐semiconductor field‐effect transistors
- Author
-
Johnson, J. G., primary, Forrest, S. R., additional, Zeisse, C. R., additional, and Nguyen, R., additional
- Published
- 1988
- Full Text
- View/download PDF
205. InP metal‐semiconductor field‐effect transistors with mercury and cadmium gates
- Author
-
Meiners, L. G., primary, Clawson, A. R., additional, and Nguyen, R., additional
- Published
- 1986
- Full Text
- View/download PDF
206. Evaluation of Geochemical Standard Reference Materials for Microanalysis
- Author
-
Nguyen, R. H. Filby Son., primary, Grimm, C. A., additional, Markowski, G. R., additional, Ekambaram, Vanavan., additional, Tanaka, Tsuyoshi., additional, and Grossman, Lawrence., additional
- Published
- 1985
- Full Text
- View/download PDF
207. Optically clocked track-and-hold for high-speed high-resolution analog-to-digital conversion
- Author
-
Jacobs, E.W., primary, Sobti, J.B., additional, Vella, V.F., additional, Nguyen, R., additional, Albares, D.J., additional, Olsen, R.B., additional, Chang, C.T., additional, Sun, S.K., additional, Choe, M.J., additional, Beccue, S., additional, Yu, R., additional, and van der Wagt, J.P.A., additional
- Full Text
- View/download PDF
208. Hardware-software aspects of shift-register based NEWS networks for the focal plane
- Author
-
Nguyen, R., primary, Mercier, D., additional, Jullian, A., additional, and Bernard, T.M., additional
- Full Text
- View/download PDF
209. InGaAs/InP submicron gate microwave power transistors for 20 GHz applications
- Author
-
Johnson, G.A., primary, Biedenbender, M.D., additional, Kapoor, V.J., additional, Messick, L.J., additional, Nguyen, R., additional, Schmitz, D., additional, and Jurgensen, H., additional
- Full Text
- View/download PDF
210. Application of laser scattering and optical defect detection methods to SIMOX-SOI wafers
- Author
-
Alles, M., primary, Dunne, J., additional, Treadwell, C., additional, Fiordalice, B., additional, and Nguyen, R., additional
- Full Text
- View/download PDF
211. Planar Fully Ion-Implanted High Power InP MISFETs
- Author
-
Messick, L., primary, Nguyen, R., additional, and Collins, D.A., additional
- Full Text
- View/download PDF
212. Application of laser scattering and optical defect detection methods to SIMOX-SOI wafers.
- Author
-
Alles, M., Dunne, J., Treadwell, C., Fiordalice, B., and Nguyen, R.
- Published
- 2001
- Full Text
- View/download PDF
213. Accidental ingestion of plastic from takeaway containers--food for thought.
- Author
-
Guirgis M, Nguyen R, Pokorny C, Guirgis, Marianne, Nguyen, Robert, and Pokorny, Christopher
- Abstract
Foreign body oesophageal obstruction is a medical emergency. It may be accidental, particularly in children, or deliberate, for example with suicide attempts. We present two cases illustrating accidental oesophageal foreign body impaction occurring after consumption of food that had been heated in a plastic container in a microwave oven, then cut and eaten directly from the softened container. To date, we are not aware of any similar reports. In view of potential complications, care needs to be taken when food is eaten directly from plastic takeaway containers. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
214. Non-coding RNA ANRIL and the number of plexiform neurofibromas in patients with NF1 microdeletions
- Author
-
Mußotter Tanja, Kluwe Lan, Högel Josef, Nguyen Rosa, Cooper David N, Mautner Victor-Felix, and Kehrer-Sawatzki Hildegard
- Subjects
Internal medicine ,RC31-1245 ,Genetics ,QH426-470 - Abstract
Abstract Background Neurofibromatosis type-1 (NF1) is caused by mutations of the NF1 gene at 17q11.2. In 95% of non-founder NF1 patients, NF1 mutations are identifiable by means of a comprehensive mutation analysis. 5-10% of these patients harbour microdeletions encompassing the NF1 gene and its flanking regions. NF1 is characterised by tumours of the peripheral nerve sheaths, the pathognomonic neurofibromas. Considerable inter- and intra-familial variation in expressivity of the disease has been observed which is influenced by genetic modifiers unrelated to the constitutional NF1 mutation. The number of plexiform neurofibromas (PNF) in NF1 patients is a highly heritable genetic trait. Recently, SNP rs2151280 located within the non-coding RNA gene ANRIL at 9p21.3, was identified as being strongly associated with PNF number in a family-based association study. The T-allele of rs2151280, which correlates with reduced ANRIL expression, appears to be associated with higher PNF number. ANRIL directly binds to the SUZ12 protein, an essential component of polycomb repressive complex 2, and is required for SUZ12 occupancy of the CDKN2A/CDKN2B tumour suppressor genes as well as for their epigenetic silencing. Methods Here, we explored a potential association of PNF number and PNF volume with SNP rs2151280 in 29 patients with constitutional NF1 microdeletions using the exact Cochran-Armitage test for trends and the exact Mann–Whitney–Wilcoxon test. Both the PNF number and total tumour volume in these 29 NF1 patients were assessed by whole-body MRI. The NF1 microdeletions observed in these 29 patients encompassed the NF1 gene as well as its flanking regions, including the SUZ12 gene. Results In the 29 microdeletion patients investigated, neither the PNF number nor PNF volume was found to be associated with the T-allele of rs2151280. Conclusion Our findings imply that, at least in patients with NF1 microdeletions, PNF susceptibility is not associated with rs2151280. Although somatic inactivation of the NF1 wild-type allele is considered to be the PNF-initiating event in NF1 patients with intragenic mutations and patients with NF1 microdeletions, both patient groups may differ with regard to tumour progression because of the heterozygous constitutional deletion of SUZ12 present only in patients with NF1 microdeletions.
- Published
- 2012
- Full Text
- View/download PDF
215. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1
- Author
-
Nguyen Rosa, Dombi Eva, Widemann Brigitte C, Solomon Jeffrey, Fuensterer Carsten, Kluwe Lan, Friedman Jan M, and Mautner Victor-Felix
- Subjects
MRI scan ,Neurofibroma ,Plexiform ,Neurofibromatosis 1 ,Tumour burden ,Medicine - Abstract
Abstract Background To examine the natural growth dynamics of internal plexiform neurofibromas (PNs) in patients with neurofibromatosis 1 (NF1). Methods Two hundred and one NF1 patients underwent whole body MRI (WBMRI). Tumour burden was estimated volumetrically. Non-parametric Spearman’s rho correlation coefficients were used to analyse the relationship of growth rate to tumour volume and age. Chi-squared and Mann–Whitney U tests were used for analysing the association of tumour occurrence with sex or age. Chi-squared tests were used to analyse the association of tumour growth with age group. Results Seventy-one of 171 patients with serial WBMRI exams had internal PNs (median follow up 2.2 years [1.1 to 4.9 years]). Median whole body tumour volume was 86.4 mL [5.2 to 5878.5 mL]) with a median growth rate of 3.7%/year (−13.4 to 111%/year) that correlated with larger whole body tumour volume (PP=0.004). No new PNs developed in 273.0 patient-years among patients without tumours. Rate of new tumour development among patients with PNs was 0.6%/year (95% confidence interval 0.02 to 3.4%). Twenty-seven (13.5%) tumours increased significantly and were more frequent among children (PP Conclusion Children with NF1 and internal PNs are at risk for tumour growth. Most PNs grow slowly or not at all, and some decrease in size. New tumours are infrequent in NF1 patients with PNs and unlikely in patients without PNs.
- Published
- 2012
- Full Text
- View/download PDF
216. Similar DNA methylation levels in specific imprinting control regions in children conceived with and without assisted reproductive technology: a cross-sectional study
- Author
-
Puumala Susan E, Nelson Heather H, Ross Julie A, Nguyen Ruby HN, Damario Mark A, and Spector Logan G
- Subjects
Assisted reproductive technology ,Epigenetics ,Imprinting ,Pediatrics ,RJ1-570 - Abstract
Abstract Background While a possible link between assisted reproductive technology (ART) and rare imprinting disorders has been found, it is not clear if this is indicative of subtler disruptions of epigenetic mechanisms. Results from previous studies have been mixed, but some methylation differences have been observed. Methods Children conceived through ART and children conceived spontaneously were recruited for this cross-sectional study. Information about reproductive history, demographic factors, birth characteristics, and infertility treatment was obtained from maternal interview and medical records. Peripheral blood lymphocytes and buccal cell samples were collected from participating children. Methylation analysis was performed on five loci using pyrosequencing. Statistical analysis of methylation differences was performed using linear regression with generalized estimating equations. Results are reported as differences with 95% confidence intervals (CI). Results A total of 67 ART children and 31 spontaneously conceived (SC) children participated. No significant difference in methylation in lymphocyte samples was observed between groups for any loci. Possible differences were found in buccal cell samples for IGF2 DMR0 (Difference: 2.07; 95% confidence interval (CI): -0.28, 4.42; p = 0.08) and IGF2R (Difference: -2.79; 95% CI: -5.74, 0.16; p = 0.06). Subgroup analysis indicated potential lower methylation in those whose parents used ART for unexplained infertility. Conclusions Observed differences in methylation between the ART and SC groups were small for all loci in the two sample types examined and no statistical differences were observed. It is still unclear whether or not small differences observed in several studies represent a real difference between groups and if this difference is biologically meaningful. Larger studies with long term follow-up are needed to fully answer these questions.
- Published
- 2012
- Full Text
- View/download PDF
217. Delineation of the clinical phenotype associated with non-mosaic type-2 NF1 deletions: two case reports
- Author
-
Vogt Julia, Nguyen Rosa, Kluwe Lan, Schuhmann Martin, Roehl Angelika C, Mußotter Tanja, Cooper David N, Mautner Victor-Felix, and Kehrer-Sawatzki Hildegard
- Subjects
Medicine - Abstract
Abstract Introduction Large deletions of the NF1 gene and its flanking regions are frequently associated with a severe clinical manifestation. Different types of gross NF1 deletion have been identified that are distinguishable both by their size and the number of genes included within the deleted regions. Type-1 NF1 deletions encompass 1.4 Mb and include 14 genes, whereas the much less common type-2 NF1 deletions span 1.2 Mb and contain 13 genes. Genotype-phenotype correlations in patients with large NF1 deletions are likely to be influenced by the nature and number of the genes deleted in addition to the NF1 gene. Whereas the clinical phenotype associated with type-1 NF1 deletions has been well documented, the detailed clinical characterization of patients with non-mosaic type-2 NF1 deletions has not so far been reported. Case presentation In the present report we characterized two Caucasian European patients with non-mosaic (germline) type-2 NF1 deletions. Our first patient was a 13-year-old girl with dysmorphic facial features, mild developmental delay, large hands and feet, hyperflexibility of the joints, macrocephaly and T2 hyperintensities in the brain. A whole-body magnetic resonance imaging scan indicated two internal plexiform neurofibromas. Our second patient was an 18-year-old man who exhibited dysmorphic facial features, developmental delay, learning disability, large hands and feet, hyperflexibility of the joints, macrocephaly and a very high subcutaneous and internal tumor load as measured volumetrically on whole-body magnetic resonance imaging scans. At the age of 18 years, he developed a malignant peripheral nerve sheath tumor and died from secondary complications. Both our patients exhibited cardiovascular malformations. Conclusions Our two patients with non-mosaic type-2 NF1 deletions exhibited clinical features that have been reported in individuals with germline type-1 NF1 deletions. Therefore, a severe disease manifestation is not confined to only patients with type-1 NF1 deletions but may also occur in individuals with type-2 NF1 deletions. Our findings support the concept of an NF1 microdeletion syndrome with severe clinical manifestation that is caused by type-1 as well as type-2 NF1 deletions.
- Published
- 2011
- Full Text
- View/download PDF
218. MIA is a potential biomarker for tumour load in neurofibromatosis type 1
- Author
-
Holtkamp Nikola, Tinschert Sigrid, Thurisch Boris, Wegener Eike, Jamsheer Aleksander, Zemojtel Tomasz, Kühnisch Jirko, Nguyen Rosa, Kossler Nadine, Mautner Victor, Kolanczyk Mateusz, Park Su-Jin, Birch Patricia, Kendler David, Harder Anja, Mundlos Stefan, and Kluwe Lan
- Subjects
Medicine - Abstract
Abstract Background Neurofibromatosis type 1 (NF1) is a frequent genetic disease characterized by multiple benign tumours with increased risk for malignancy. There is currently no biomarker for tumour load in NF1 patients. Methods In situ hybridization and quantitative real-time polymerase reaction were applied to investigate expression of cartilage-specific genes in mice bearing conditional inactivation of NF1 in the developing limbs. These mice do not develop tumours but recapitulate aspects of NF1 bone dysplasia, including deregulation of cartilage differentiation. It has been recently shown that NF1 tumours require for their growth the master regulator of cartilage differentiation SOX9. We thus hypothesized that some of the cartilage-specific genes deregulated in an Nf1Prx1 mouse model might prove to be relevant biomarkers of NF1 tumours. We tested this hypothesis by analyzing expression of the SOX9 target gene product melanoma-inhibitory activity/cd-rap (MIA) in tumour and serum samples of NF1 patients. Results Increased expression of Mia was found in Nf1-deficient cartilage in mice. In humans, MIA was expressed in all NF1-related tumours and its serum levels were significantly higher in NF1 patients than in healthy controls. Among NF1 patients, MIA serum levels were significantly higher in those with plexiform neurofibromas and in those with large number of cutaneous (> 1,000) or subcutaneous (> 100) neurofibromas than in patients without such tumours. Most notably, MIA serum levels correlated significantly with internal tumour burden. Conclusions MIA is a potential serum biomarker of tumour load in NF1 patients which could be useful in following the disease course and monitoring the efficacy of therapies.
- Published
- 2011
- Full Text
- View/download PDF
219. DIII-D research advancing the physics basis for optimizing the tokamak approach to fusion energy
- Author
-
M. E. Fenstermacher, J. Abbate, S. Abe, T. Abrams, M. Adams, B. Adamson, N. Aiba, T. Akiyama, P. Aleynikov, E. Allen, S. Allen, H. Anand, J. Anderson, Y. Andrew, T. Andrews, D. Appelt, R. Arbon, N. Ashikawa, A. Ashourvan, M. Aslin, Y. Asnis, M. Austin, D. Ayala, J. Bak, I. Bandyopadhyay, S. Banerjee, K. Barada, L. Bardoczi, J. Barr, E. Bass, D. Battaglia, A. Battey, W. Baumgartner, L. Baylor, J. Beckers, M. Beidler, E. Belli, J. Berkery, T. Bernard, N. Bertelli, M. Beurskens, R. Bielajew, S. Bilgili, B. Biswas, S. Blondel, J. Boedo, I. Bogatu, R. Boivin, T. Bolzonella, M. Bongard, X. Bonnin, P. Bonoli, M. Bonotto, A. Bortolon, S. Bose, N. Bosviel, S. Bouwmans, M. Boyer, W. Boyes, L. Bradley, R. Brambila, D. Brennan, S. Bringuier, L. Brodsky, M. Brookman, J. Brooks, D. Brower, G. Brown, W. Brown, M. Burke, K. Burrell, K. Butler, R. Buttery, I. Bykov, P. Byrne, A. Cacheris, K. Callahan, J. Callen, G. Campbell, J. Candy, J. Canik, P. Cano-Megias, N. Cao, L. Carayannopoulos, T. Carlstrom, W. Carrig, T. Carter, W. Cary, L. Casali, M. Cengher, G. Cespedes Paz, R. Chaban, V. Chan, B. Chapman, I. Char, A. Chattopadhyay, R. Chen, J. Chen, X. Chen, M. Chen, Z. Chen, M. Choi, W. Choi, G. Choi, L. Chousal, C. Chrobak, C. Chrystal, Y. Chung, R. Churchill, M. Cianciosa, J. Clark, M. Clement, S. Coda, A. Cole, C. Collins, W. Conlin, A. Cooper, J. Cordell, B. Coriton, T. Cote, J. Cothran, A. Creely, N. Crocker, C. Crowe, B. Crowley, T. Crowley, D. Cruz-Zabala, D. Cummings, M. Curie, D. Curreli, A. Dal Molin, B. Dannels, A. Dautt-Silva, K. Davda, G. De Tommasi, P. De Vries, G. Degrandchamp, J. Degrassie, D. Demers, S. Denk, S. Depasquale, E. Deshazer, A. Diallo, S. Diem, A. Dimits, R. Ding, S. Ding, W. Ding, T. Do, J. Doane, G. Dong, D. Donovan, J. Drake, W. Drews, J. Drobny, X. Du, H. Du, V. Duarte, D. Dudt, C. Dunn, J. Duran, A. Dvorak, F. Effenberg, N. Eidietis, D. Elder, D. Eldon, R. Ellis, W. Elwasif, D. Ennis, K. Erickson, D. Ernst, M. Fasciana, D. Fedorov, E. Feibush, N. Ferraro, J. Ferreira, J. Ferron, P. Fimognari, D. Finkenthal, R. Fitzpatrick, P. Fox, W. Fox, L. Frassinetti, H. Frerichs, H. Frye, Y. Fu, K. Gage, J. Galdon Quiroga, A. Gallo, Q. Gao, A. Garcia, M. Garcia Munoz, D. Garnier, A. Garofalo, A. Gattuso, D. Geng, K. Gentle, D. Ghosh, L. Giacomelli, S. Gibson, E. Gilson, C. Giroud, F. Glass, A. Glasser, D. Glibert, P. Gohil, R. Gomez, S. Gomez, X. Gong, E. Gonzales, A. Goodman, Y. Gorelov, V. Graber, R. Granetz, T. Gray, D. Green, C. Greenfield, M. Greenwald, B. Grierson, R. Groebner, W. Grosnickle, M. Groth, H. Grunloh, S. Gu, W. Guo, H. Guo, P. Gupta, J. Guterl, W. Guttenfelder, T. Guzman, S. Haar, R. Hager, S. Hahn, M. Halfmoon, T. Hall, K. Hallatschek, F. Halpern, G. Hammett, H. Han, E. Hansen, C. Hansen, M. Hansink, J. Hanson, M. Hanson, G. Hao, A. Harris, R. Harvey, S. Haskey, E. Hassan, A. Hassanein, D. Hatch, R. Hawryluk, W. Hayashi, W. Heidbrink, J. Herfindal, J. Hicok, D. Hill, E. Hinson, C. Holcomb, L. Holland, C. Holland, E. Hollmann, J. Hollocombe, A. Holm, I. Holmes, K. Holtrop, M. Honda, R. Hong, R. Hood, A. Horton, L. Horvath, M. Hosokawa, S. Houshmandyar, N. Howard, E. Howell, D. Hoyt, W. Hu, Y. Hu, Q. Hu, J. Huang, Y. Huang, J. Hughes, T. Human, D. Humphreys, P. Huynh, A. Hyatt, C. Ibanez, L. Ibarra, R. Icasas, K. Ida, V. Igochine, Y. In, S. Inoue, A. Isayama, O. Izacard, V. Izzo, A. Jackson, G. Jacobsen, A. Jaervinen, A. Jalalvand, J. Janhunen, S. Jardin, H. Jarleblad, Y. Jeon, H. Ji, X. Jian, E. Joffrin, A. Johansen, C. Johnson, T. Johnson, C. Jones, I. Joseph, D. Jubas, B. Junge, W. Kalb, R. Kalling, C. Kamath, J. Kang, D. Kaplan, A. Kaptanoglu, S. Kasdorf, J. Kates-Harbeck, P. Kazantzidis, A. Kellman, D. Kellman, C. Kessel, K. Khumthong, E. Kim, H. Kim, J. Kim, S. Kim, K. Kim, C. Kim, W. Kimura, M. King, J. King, J. Kinsey, A. Kirk, B. Kiyan, A. Kleiner, V. Klevarova, R. Knapp, M. Knolker, W. Ko, T. Kobayashi, E. Koch, M. Kochan, B. Koel, M. Koepke, A. Kohn, R. Kolasinski, E. Kolemen, E. Kostadinova, M. Kostuk, G. Kramer, D. Kriete, L. Kripner, S. Kubota, J. Kulchar, K. Kwon, R. La Haye, F. Laggner, H. Lan, R. Lantsov, L. Lao, A. Lasa Esquisabel, C. Lasnier, C. Lau, B. Leard, J. Lee, R. Lee, M. Lee, Y. Lee, C. Lee, S. Lee, M. Lehnen, A. Leonard, E. Leppink, M. Lesher, J. Lestz, J. Leuer, N. Leuthold, X. Li, K. Li, E. Li, G. Li, L. Li, Z. Li, J. Li, Y. Li, Z. Lin, D. Lin, X. Liu, J. Liu, Y. Liu, T. Liu, C. Liu, Z. Liu, D. Liu, A. Liu, A. Loarte-Prieto, L. Lodestro, N. Logan, J. Lohr, B. Lombardo, J. Lore, Q. Luan, T. Luce, T. Luda Di Cortemiglia, N. Luhmann, R. Lunsford, Z. Luo, A. Lvovskiy, B. Lyons, X. Ma, M. Madruga, B. Madsen, C. Maggi, K. Maheshwari, A. Mail, J. Mailloux, R. Maingi, M. Major, M. Makowski, R. Manchanda, C. Marini, A. Marinoni, A. Maris, T. Markovic, L. Marrelli, E. Martin, J. Mateja, G. Matsunaga, R. Maurizio, P. Mauzey, D. Mauzey, G. Mcardle, J. Mcclenaghan, K. Mccollam, C. Mcdevitt, K. Mckay, G. Mckee, A. Mclean, V. Mehta, E. Meier, J. Menard, O. Meneghini, G. Merlo, S. Messer, W. Meyer, C. Michael, C. Michoski, P. Milne, G. Minet, A. Misleh, Y. Mitrishkin, C. Moeller, K. Montes, M. Morales, S. Mordijck, D. Moreau, S. Morosohk, P. Morris, L. Morton, A. Moser, R. Moyer, C. Moynihan, T. Mrazkova, D. Mueller, S. Munaretto, J. Munoz Burgos, C. Murphy, K. Murphy, C. Muscatello, C. Myers, A. Nagy, G. Nandipati, M. Navarro, F. Nave, G. Navratil, R. Nazikian, A. Neff, G. Neilson, T. Neiser, W. Neiswanger, D. Nelson, A. Nelson, F. Nespoli, R. Nguyen, L. Nguyen, X. Nguyen, J. Nichols, M. Nocente, S. Nogami, S. Noraky, N. Norausky, M. Nornberg, R. Nygren, T. Odstrcil, D. Ogas, T. Ogorman, S. Ohdachi, Y. Ohtani, M. Okabayashi, M. Okamoto, L. Olavson, E. Olofsson, M. Omullane, R. Oneill, D. Orlov, W. Orvis, T. Osborne, D. Pace, G. Paganini Canal, A. Pajares Martinez, L. Palacios, C. Pan, Q. Pan, R. Pandit, M. Pandya, A. Pankin, Y. Park, J. Park, S. Parker, P. Parks, M. Parsons, B. Patel, C. Pawley, C. Paz-Soldan, W. Peebles, S. Pelton, R. Perillo, C. Petty, Y. Peysson, D. Pierce, A. Pigarov, L. Pigatto, D. Piglowski, S. Pinches, R. Pinsker, P. Piovesan, N. Piper, A. Pironti, R. Pitts, J. Pizzo, U. Plank, M. Podesta, E. Poli, F. Poli, D. Ponce, Z. Popovic, M. Porkolab, G. Porter, C. Powers, S. Powers, R. Prater, Q. Pratt, I. Pusztai, J. Qian, X. Qin, O. Ra, T. Rafiq, T. Raines, R. Raman, J. Rauch, A. Raymond, C. Rea, M. Reich, A. Reiman, S. Reinhold, M. Reinke, R. Reksoatmodjo, Q. Ren, Y. Ren, J. Ren, M. Rensink, J. Renteria, T. Rhodes, J. Rice, R. Roberts, J. Robinson, P. Rodriguez Fernandez, T. Rognlien, A. Rosenthal, S. Rosiello, J. Rost, J. Roveto, W. Rowan, R. Rozenblat, J. Ruane, D. Rudakov, J. Ruiz Ruiz, R. Rupani, S. Saarelma, S. Sabbagh, J. Sachdev, J. Saenz, S. Saib, M. Salewski, A. Salmi, B. Sammuli, C. Samuell, A. Sandorfi, C. Sang, J. Sarff, O. Sauter, K. Schaubel, L. Schmitz, O. Schmitz, J. Schneider, P. Schroeder, K. Schultz, E. Schuster, J. Schwartz, F. Sciortino, F. Scotti, J. Scoville, A. Seltzman, S. Seol, I. Sfiligoi, M. Shafer, S. Sharapov, H. Shen, Z. Sheng, T. Shepard, S. Shi, Y. Shibata, G. Shin, D. Shiraki, R. Shousha, H. Si, P. Simmerling, G. Sinclair, J. Sinha, P. Sinha, G. Sips, T. Sizyuk, C. Skinner, A. Sladkomedova, T. Slendebroek, J. Slief, R. Smirnov, J. Smith, S. Smith, D. Smith, J. Snipes, G. Snoep, A. Snyder, P. Snyder, E. Solano, W. Solomon, J. Song, A. Sontag, V. Soukhanovskii, J. Spendlove, D. Spong, J. Squire, C. Srinivasan, W. Stacey, G. Staebler, L. Stagner, T. Stange, P. Stangeby, R. Stefan, R. Stemprok, D. Stephan, J. Stillerman, T. Stoltzfus-Dueck, W. Stonecipher, S. Storment, E. Strait, D. Su, L. Sugiyama, Y. Sun, P. Sun, Z. Sun, A. Sun, D. Sundstrom, C. Sung, J. Sungcoco, W. Suttrop, Y. Suzuki, T. Suzuki, A. Svyatkovskiy, C. Swee, R. Sweeney, C. Sweetnam, G. Szepesi, M. Takechi, T. Tala, K. Tanaka, X. Tang, S. Tang, Y. Tao, R. Tao, D. Taussig, T. Taylor, K. Teixeira, K. Teo, A. Theodorsen, D. Thomas, K. Thome, A. Thorman, A. Thornton, A. Ti, M. Tillack, N. Timchenko, R. Tinguely, R. Tompkins, J. Tooker, A. Torrezan De Sousa, G. Trevisan, S. Tripathi, A. Trujillo Ochoa, D. Truong, C. Tsui, F. Turco, A. Turnbull, M. Umansky, E. Unterberg, P. Vaezi, P. Vail, J. Valdez, W. Valkis, B. Van Compernolle, J. Van Galen, R. Van Kampen, M. Van Zeeland, G. Verdoolaege, N. Vianello, B. Victor, E. Viezzer, S. Vincena, M. Wade, F. Waelbroeck, J. Wai, T. Wakatsuki, M. Walker, G. Wallace, R. Waltz, W. Wampler, L. Wang, H. Wang, Y. Wang, Z. Wang, G. Wang, S. Ward, M. Watkins, J. Watkins, W. Wehner, Y. Wei, M. Weiland, D. Weisberg, A. Welander, A. White, R. White, S. Wiesen, R. Wilcox, T. Wilks, M. Willensdorfer, H. Wilson, A. Wingen, M. Wolde, M. Wolff, K. Woller, A. Wolz, H. Wong, S. Woodruff, M. Wu, Y. Wu, S. Wukitch, G. Wurden, W. Xiao, R. Xie, Z. Xing, X. Xu, C. Xu, G. Xu, Z. Yan, X. Yang, S. Yang, T. Yokoyama, R. Yoneda, M. Yoshida, K. You, T. Younkin, J. Yu, M. Yu, G. Yu, Q. Yuan, L. Zaidenberg, L. Zakharov, A. Zamengo, S. Zamperini, M. Zarnstorff, E. Zeger, K. Zeller, L. Zeng, M. Zerbini, L. Zhang, X. Zhang, R. Zhang, B. Zhang, J. Zhang, L. Zhao, B. Zhao, Y. Zheng, L. Zheng, B. Zhu, J. Zhu, Y. Zhu, M. Zsutty, M. Zuin, Fenstermacher, M. E., Abbate, J., Abe, S., Abrams, T., Adams, M., Adamson, B., Aiba, N., Akiyama, T., Aleynikov, P., Allen, E., Allen, S., Anand, H., Anderson, J., Andrew, Y., Andrews, T., Appelt, D., Arbon, R., Ashikawa, N., Ashourvan, A., Aslin, M., Asnis, Y., Austin, M., Ayala, D., Bak, J., Bandyopadhyay, I., Banerjee, S., Barada, K., Bardoczi, L., Barr, J., Bass, E., Battaglia, D., Battey, A., Baumgartner, W., Baylor, L., Beckers, J., Beidler, M., Belli, E., Berkery, J., Bernard, T., Bertelli, N., Beurskens, M., Bielajew, R., Bilgili, S., Biswas, B., Blondel, S., Boedo, J., Bogatu, I., Boivin, R., Bolzonella, T., Bongard, M., Bonnin, X., Bonoli, P., Bonotto, M., Bortolon, A., Bose, S., Bosviel, N., Bouwmans, S., Boyer, M., Boyes, W., Bradley, L., Brambila, R., Brennan, D., Bringuier, S., Brodsky, L., Brookman, M., Brooks, J., Brower, D., Brown, G., Brown, W., Burke, M., Burrell, K., Butler, K., Buttery, R., Bykov, I., Byrne, P., Cacheris, A., Callahan, K., Callen, J., Campbell, G., Candy, J., Canik, J., Cano-Megias, P., Cao, N., Carayannopoulos, L., Carlstrom, T., Carrig, W., Carter, T., Cary, W., Casali, L., Cengher, M., Cespedes Paz, G., Chaban, R., Chan, V., Chapman, B., Char, I., Chattopadhyay, A., Chen, R., Chen, J., Chen, X., Chen, M., Chen, Z., Choi, M., Choi, W., Choi, G., Chousal, L., Chrobak, C., Chrystal, C., Chung, Y., Churchill, R., Cianciosa, M., Clark, J., Clement, M., Coda, S., Cole, A., Collins, C., Conlin, W., Cooper, A., Cordell, J., Coriton, B., Cote, T., Cothran, J., Creely, A., Crocker, N., Crowe, C., Crowley, B., Crowley, T., Cruz-Zabala, D., Cummings, D., Curie, M., Curreli, D., Dal Molin, A., Dannels, B., Dautt-Silva, A., Davda, K., De Tommasi, G., De Vries, P., Degrandchamp, G., Degrassie, J., Demers, D., Denk, S., Depasquale, S., Deshazer, E., Diallo, A., Diem, S., Dimits, A., Ding, R., Ding, S., Ding, W., Do, T., Doane, J., Dong, G., Donovan, D., Drake, J., Drews, W., Drobny, J., Du, X., Du, H., Duarte, V., Dudt, D., Dunn, C., Duran, J., Dvorak, A., Effenberg, F., Eidietis, N., Elder, D., Eldon, D., Ellis, R., Elwasif, W., Ennis, D., Erickson, K., Ernst, D., Fasciana, M., Fedorov, D., Feibush, E., Ferraro, N., Ferreira, J., Ferron, J., Fimognari, P., Finkenthal, D., Fitzpatrick, R., Fox, P., Fox, W., Frassinetti, L., Frerichs, H., Frye, H., Fu, Y., Gage, K., Galdon Quiroga, J., Gallo, A., Gao, Q., Garcia, A., Garcia Munoz, M., Garnier, D., Garofalo, A., Gattuso, A., Geng, D., Gentle, K., Ghosh, D., Giacomelli, L., Gibson, S., Gilson, E., Giroud, C., Glass, F., Glasser, A., Glibert, D., Gohil, P., Gomez, R., Gomez, S., Gong, X., Gonzales, E., Goodman, A., Gorelov, Y., Graber, V., Granetz, R., Gray, T., Green, D., Greenfield, C., Greenwald, M., Grierson, B., Groebner, R., Grosnickle, W., Groth, M., Grunloh, H., Gu, S., Guo, W., Guo, H., Gupta, P., Guterl, J., Guttenfelder, W., Guzman, T., Haar, S., Hager, R., Hahn, S., Halfmoon, M., Hall, T., Hallatschek, K., Halpern, F., Hammett, G., Han, H., Hansen, E., Hansen, C., Hansink, M., Hanson, J., Hanson, M., Hao, G., Harris, A., Harvey, R., Haskey, S., Hassan, E., Hassanein, A., Hatch, D., Hawryluk, R., Hayashi, W., Heidbrink, W., Herfindal, J., Hicok, J., Hill, D., Hinson, E., Holcomb, C., Holland, L., Holland, C., Hollmann, E., Hollocombe, J., Holm, A., Holmes, I., Holtrop, K., Honda, M., Hong, R., Hood, R., Horton, A., Horvath, L., Hosokawa, M., Houshmandyar, S., Howard, N., Howell, E., Hoyt, D., Hu, W., Hu, Y., Hu, Q., Huang, J., Huang, Y., Hughes, J., Human, T., Humphreys, D., Huynh, P., Hyatt, A., Ibanez, C., Ibarra, L., Icasas, R., Ida, K., Igochine, V., In, Y., Inoue, S., Isayama, A., Izacard, O., Izzo, V., Jackson, A., Jacobsen, G., Jaervinen, A., Jalalvand, A., Janhunen, J., Jardin, S., Jarleblad, H., Jeon, Y., Ji, H., Jian, X., Joffrin, E., Johansen, A., Johnson, C., Johnson, T., Jones, C., Joseph, I., Jubas, D., Junge, B., Kalb, W., Kalling, R., Kamath, C., Kang, J., Kaplan, D., Kaptanoglu, A., Kasdorf, S., Kates-Harbeck, J., Kazantzidis, P., Kellman, A., Kellman, D., Kessel, C., Khumthong, K., Kim, E., Kim, H., Kim, J., Kim, S., Kim, K., Kim, C., Kimura, W., King, M., King, J., Kinsey, J., Kirk, A., Kiyan, B., Kleiner, A., Klevarova, V., Knapp, R., Knolker, M., Ko, W., Kobayashi, T., Koch, E., Kochan, M., Koel, B., Koepke, M., Kohn, A., Kolasinski, R., Kolemen, E., Kostadinova, E., Kostuk, M., Kramer, G., Kriete, D., Kripner, L., Kubota, S., Kulchar, J., Kwon, K., La Haye, R., Laggner, F., Lan, H., Lantsov, R., Lao, L., Lasa Esquisabel, A., Lasnier, C., Lau, C., Leard, B., Lee, J., Lee, R., Lee, M., Lee, Y., Lee, C., Lee, S., Lehnen, M., Leonard, A., Leppink, E., Lesher, M., Lestz, J., Leuer, J., Leuthold, N., Li, X., Li, K., Li, E., Li, G., Li, L., Li, Z., Li, J., Li, Y., Lin, Z., Lin, D., Liu, X., Liu, J., Liu, Y., Liu, T., Liu, C., Liu, Z., Liu, D., Liu, A., Loarte-Prieto, A., Lodestro, L., Logan, N., Lohr, J., Lombardo, B., Lore, J., Luan, Q., Luce, T., Luda Di Cortemiglia, T., Luhmann, N., Lunsford, R., Luo, Z., Lvovskiy, A., Lyons, B., Ma, X., Madruga, M., Madsen, B., Maggi, C., Maheshwari, K., Mail, A., Mailloux, J., Maingi, R., Major, M., Makowski, M., Manchanda, R., Marini, C., Marinoni, A., Maris, A., Markovic, T., Marrelli, L., Martin, E., Mateja, J., Matsunaga, G., Maurizio, R., Mauzey, P., Mauzey, D., Mcardle, G., Mcclenaghan, J., Mccollam, K., Mcdevitt, C., Mckay, K., Mckee, G., Mclean, A., Mehta, V., Meier, E., Menard, J., Meneghini, O., Merlo, G., Messer, S., Meyer, W., Michael, C., Michoski, C., Milne, P., Minet, G., Misleh, A., Mitrishkin, Y., Moeller, C., Montes, K., Morales, M., Mordijck, S., Moreau, D., Morosohk, S., Morris, P., Morton, L., Moser, A., Moyer, R., Moynihan, C., Mrazkova, T., Mueller, D., Munaretto, S., Munoz Burgos, J., Murphy, C., Murphy, K., Muscatello, C., Myers, C., Nagy, A., Nandipati, G., Navarro, M., Nave, F., Navratil, G., Nazikian, R., Neff, A., Neilson, G., Neiser, T., Neiswanger, W., Nelson, D., Nelson, A., Nespoli, F., Nguyen, R., Nguyen, L., Nguyen, X., Nichols, J., Nocente, M., Nogami, S., Noraky, S., Norausky, N., Nornberg, M., Nygren, R., Odstrcil, T., Ogas, D., Ogorman, T., Ohdachi, S., Ohtani, Y., Okabayashi, M., Okamoto, M., Olavson, L., Olofsson, E., Omullane, M., Oneill, R., Orlov, D., Orvis, W., Osborne, T., Pace, D., Paganini Canal, G., Pajares Martinez, A., Palacios, L., Pan, C., Pan, Q., Pandit, R., Pandya, M., Pankin, A., Park, Y., Park, J., Parker, S., Parks, P., Parsons, M., Patel, B., Pawley, C., Paz-Soldan, C., Peebles, W., Pelton, S., Perillo, R., Petty, C., Peysson, Y., Pierce, D., Pigarov, A., Pigatto, L., Piglowski, D., Pinches, S., Pinsker, R., Piovesan, P., Piper, N., Pironti, A., Pitts, R., Pizzo, J., Plank, U., Podesta, M., Poli, E., Poli, F., Ponce, D., Popovic, Z., Porkolab, M., Porter, G., Powers, C., Powers, S., Prater, R., Pratt, Q., Pusztai, I., Qian, J., Qin, X., Ra, O., Rafiq, T., Raines, T., Raman, R., Rauch, J., Raymond, A., Rea, C., Reich, M., Reiman, A., Reinhold, S., Reinke, M., Reksoatmodjo, R., Ren, Q., Ren, Y., Ren, J., Rensink, M., Renteria, J., Rhodes, T., Rice, J., Roberts, R., Robinson, J., Rodriguez Fernandez, P., Rognlien, T., Rosenthal, A., Rosiello, S., Rost, J., Roveto, J., Rowan, W., Rozenblat, R., Ruane, J., Rudakov, D., Ruiz Ruiz, J., Rupani, R., Saarelma, S., Sabbagh, S., Sachdev, J., Saenz, J., Saib, S., Salewski, M., Salmi, A., Sammuli, B., Samuell, C., Sandorfi, A., Sang, C., Sarff, J., Sauter, O., Schaubel, K., Schmitz, L., Schmitz, O., Schneider, J., Schroeder, P., Schultz, K., Schuster, E., Schwartz, J., Sciortino, F., Scotti, F., Scoville, J., Seltzman, A., Seol, S., Sfiligoi, I., Shafer, M., Sharapov, S., Shen, H., Sheng, Z., Shepard, T., Shi, S., Shibata, Y., Shin, G., Shiraki, D., Shousha, R., Si, H., Simmerling, P., Sinclair, G., Sinha, J., Sinha, P., Sips, G., Sizyuk, T., Skinner, C., Sladkomedova, A., Slendebroek, T., Slief, J., Smirnov, R., Smith, J., Smith, S., Smith, D., Snipes, J., Snoep, G., Snyder, A., Snyder, P., Solano, E., Solomon, W., Song, J., Sontag, A., Soukhanovskii, V., Spendlove, J., Spong, D., Squire, J., Srinivasan, C., Stacey, W., Staebler, G., Stagner, L., Stange, T., Stangeby, P., Stefan, R., Stemprok, R., Stephan, D., Stillerman, J., Stoltzfus-Dueck, T., Stonecipher, W., Storment, S., Strait, E., Su, D., Sugiyama, L., Sun, Y., Sun, P., Sun, Z., Sun, A., Sundstrom, D., Sung, C., Sungcoco, J., Suttrop, W., Suzuki, Y., Suzuki, T., Svyatkovskiy, A., Swee, C., Sweeney, R., Sweetnam, C., Szepesi, G., Takechi, M., Tala, T., Tanaka, K., Tang, X., Tang, S., Tao, Y., Tao, R., Taussig, D., Taylor, T., Teixeira, K., Teo, K., Theodorsen, A., Thomas, D., Thome, K., Thorman, A., Thornton, A., Ti, A., Tillack, M., Timchenko, N., Tinguely, R., Tompkins, R., Tooker, J., Torrezan De Sousa, A., Trevisan, G., Tripathi, S., Trujillo Ochoa, A., Truong, D., Tsui, C., Turco, F., Turnbull, A., Umansky, M., Unterberg, E., Vaezi, P., Vail, P., Valdez, J., Valkis, W., Van Compernolle, B., Van Galen, J., Van Kampen, R., Van Zeeland, M., Verdoolaege, G., Vianello, N., Victor, B., Viezzer, E., Vincena, S., Wade, M., Waelbroeck, F., Wai, J., Wakatsuki, T., Walker, M., Wallace, G., Waltz, R., Wampler, W., Wang, L., Wang, H., Wang, Y., Wang, Z., Wang, G., Ward, S., Watkins, M., Watkins, J., Wehner, W., Wei, Y., Weiland, M., Weisberg, D., Welander, A., White, A., White, R., Wiesen, S., Wilcox, R., Wilks, T., Willensdorfer, M., Wilson, H., Wingen, A., Wolde, M., Wolff, M., Woller, K., Wolz, A., Wong, H., Woodruff, S., Wu, M., Wu, Y., Wukitch, S., Wurden, G., Xiao, W., Xie, R., Xing, Z., Xu, X., Xu, C., Xu, G., Yan, Z., Yang, X., Yang, S., Yokoyama, T., Yoneda, R., Yoshida, M., You, K., Younkin, T., Yu, J., Yu, M., Yu, G., Yuan, Q., Zaidenberg, L., Zakharov, L., Zamengo, A., Zamperini, S., Zarnstorff, M., Zeger, E., Zeller, K., Zeng, L., Zerbini, M., Zhang, L., Zhang, X., Zhang, R., Zhang, B., Zhang, J., Zhao, L., Zhao, B., Zheng, Y., Zheng, L., Zhu, B., Zhu, J., Zhu, Y., Zsutty, M., Zuin, M., Fenstermacher, M, Abbate, J, Abe, S, Abrams, T, Adams, M, Adamson, B, Aiba, N, Akiyama, T, Aleynikov, P, Allen, E, Allen, S, Anand, H, Anderson, J, Andrew, Y, Andrews, T, Appelt, D, Arbon, R, Ashikawa, N, Ashourvan, A, Aslin, M, Asnis, Y, Austin, M, Ayala, D, Bak, J, Bandyopadhyay, I, Banerjee, S, Barada, K, Bardoczi, L, Barr, J, Bass, E, Battaglia, D, Battey, A, Baumgartner, W, Baylor, L, Beckers, J, Beidler, M, Belli, E, Berkery, J, Bernard, T, Bertelli, N, Beurskens, M, Bielajew, R, Bilgili, S, Biswas, B, Blondel, S, Boedo, J, Bogatu, I, Boivin, R, Bolzonella, T, Bongard, M, Bonnin, X, Bonoli, P, Bonotto, M, Bortolon, A, Bose, S, Bosviel, N, Bouwmans, S, Boyer, M, Boyes, W, Bradley, L, Brambila, R, Brennan, D, Bringuier, S, Brodsky, L, Brookman, M, Brooks, J, Brower, D, Brown, G, Brown, W, Burke, M, Burrell, K, Butler, K, Buttery, R, Bykov, I, Byrne, P, Cacheris, A, Callahan, K, Callen, J, Campbell, G, Candy, J, Canik, J, Cano-Megias, P, Cao, N, Carayannopoulos, L, Carlstrom, T, Carrig, W, Carter, T, Cary, W, Casali, L, Cengher, M, Paz, G, Chaban, R, Chan, V, Chapman, B, Char, I, Chattopadhyay, A, Chen, R, Chen, J, Chen, X, Chen, M, Chen, Z, Choi, M, Choi, W, Choi, G, Chousal, L, Chrobak, C, Chrystal, C, Chung, Y, Churchill, R, Cianciosa, M, Clark, J, Clement, M, Coda, S, Cole, A, Collins, C, Conlin, W, Cooper, A, Cordell, J, Coriton, B, Cote, T, Cothran, J, Creely, A, Crocker, N, Crowe, C, Crowley, B, Crowley, T, Cruz-Zabala, D, Cummings, D, Curie, M, Curreli, D, Dal Molin, A, Dannels, B, Dautt-Silva, A, Davda, K, De Tommasi, G, De Vries, P, Degrandchamp, G, Degrassie, J, Demers, D, Denk, S, Depasquale, S, Deshazer, E, Diallo, A, Diem, S, Dimits, A, Ding, R, Ding, S, Ding, W, Do, T, Doane, J, Dong, G, Donovan, D, Drake, J, Drews, W, Drobny, J, Du, X, Du, H, Duarte, V, Dudt, D, Dunn, C, Duran, J, Dvorak, A, Effenberg, F, Eidietis, N, Elder, D, Eldon, D, Ellis, R, Elwasif, W, Ennis, D, Erickson, K, Ernst, D, Fasciana, M, Fedorov, D, Feibush, E, Ferraro, N, Ferreira, J, Ferron, J, Fimognari, P, Finkenthal, D, Fitzpatrick, R, Fox, P, Fox, W, Frassinetti, L, Frerichs, H, Frye, H, Fu, Y, Gage, K, Quiroga, J, Gallo, A, Gao, Q, Garcia, A, Munoz, M, Garnier, D, Garofalo, A, Gattuso, A, Geng, D, Gentle, K, Ghosh, D, Giacomelli, L, Gibson, S, Gilson, E, Giroud, C, Glass, F, Glasser, A, Glibert, D, Gohil, P, Gomez, R, Gomez, S, Gong, X, Gonzales, E, Goodman, A, Gorelov, Y, Graber, V, Granetz, R, Gray, T, Green, D, Greenfield, C, Greenwald, M, Grierson, B, Groebner, R, Grosnickle, W, Groth, M, Grunloh, H, Gu, S, Guo, W, Guo, H, Gupta, P, Guterl, J, Guttenfelder, W, Guzman, T, Haar, S, Hager, R, Hahn, S, Halfmoon, M, Hall, T, Hallatschek, K, Halpern, F, Hammett, G, Han, H, Hansen, E, Hansen, C, Hansink, M, Hanson, J, Hanson, M, Hao, G, Harris, A, Harvey, R, Haskey, S, Hassan, E, Hassanein, A, Hatch, D, Hawryluk, R, Hayashi, W, Heidbrink, W, Herfindal, J, Hicok, J, Hill, D, Hinson, E, Holcomb, C, Holland, L, Holland, C, Hollmann, E, Hollocombe, J, Holm, A, Holmes, I, Holtrop, K, Honda, M, Hong, R, Hood, R, Horton, A, Horvath, L, Hosokawa, M, Houshmandyar, S, Howard, N, Howell, E, Hoyt, D, Hu, W, Hu, Y, Hu, Q, Huang, J, Huang, Y, Hughes, J, Human, T, Humphreys, D, Huynh, P, Hyatt, A, Ibanez, C, Ibarra, L, Icasas, R, Ida, K, Igochine, V, In, Y, Inoue, S, Isayama, A, Izacard, O, Izzo, V, Jackson, A, Jacobsen, G, Jaervinen, A, Jalalvand, A, Janhunen, J, Jardin, S, Jarleblad, H, Jeon, Y, Ji, H, Jian, X, Joffrin, E, Johansen, A, Johnson, C, Johnson, T, Jones, C, Joseph, I, Jubas, D, Junge, B, Kalb, W, Kalling, R, Kamath, C, Kang, J, Kaplan, D, Kaptanoglu, A, Kasdorf, S, Kates-Harbeck, J, Kazantzidis, P, Kellman, A, Kellman, D, Kessel, C, Khumthong, K, Kim, E, Kim, H, Kim, J, Kim, S, Kim, K, Kim, C, Kimura, W, King, M, King, J, Kinsey, J, Kirk, A, Kiyan, B, Kleiner, A, Klevarova, V, Knapp, R, Knolker, M, Ko, W, Kobayashi, T, Koch, E, Kochan, M, Koel, B, Koepke, M, Kohn, A, Kolasinski, R, Kolemen, E, Kostadinova, E, Kostuk, M, Kramer, G, Kriete, D, Kripner, L, Kubota, S, Kulchar, J, Kwon, K, La Haye, R, Laggner, F, Lan, H, Lantsov, R, Lao, L, Esquisabel, A, Lasnier, C, Lau, C, Leard, B, Lee, J, Lee, R, Lee, M, Lee, Y, Lee, C, Lee, S, Lehnen, M, Leonard, A, Leppink, E, Lesher, M, Lestz, J, Leuer, J, Leuthold, N, Li, X, Li, K, Li, E, Li, G, Li, L, Li, Z, Li, J, Li, Y, Lin, Z, Lin, D, Liu, X, Liu, J, Liu, Y, Liu, T, Liu, C, Liu, Z, Liu, D, Liu, A, Loarte-Prieto, A, Lodestro, L, Logan, N, Lohr, J, Lombardo, B, Lore, J, Luan, Q, Luce, T, Di Cortemiglia, T, Luhmann, N, Lunsford, R, Luo, Z, Lvovskiy, A, Lyons, B, Ma, X, Madruga, M, Madsen, B, Maggi, C, Maheshwari, K, Mail, A, Mailloux, J, Maingi, R, Major, M, Makowski, M, Manchanda, R, Marini, C, Marinoni, A, Maris, A, Markovic, T, Marrelli, L, Martin, E, Mateja, J, Matsunaga, G, Maurizio, R, Mauzey, P, Mauzey, D, Mcardle, G, Mcclenaghan, J, Mccollam, K, Mcdevitt, C, Mckay, K, Mckee, G, Mclean, A, Mehta, V, Meier, E, Menard, J, Meneghini, O, Merlo, G, Messer, S, Meyer, W, Michael, C, Michoski, C, Milne, P, Minet, G, Misleh, A, Mitrishkin, Y, Moeller, C, Montes, K, Morales, M, Mordijck, S, Moreau, D, Morosohk, S, Morris, P, Morton, L, Moser, A, Moyer, R, Moynihan, C, Mrazkova, T, Mueller, D, Munaretto, S, Burgos, J, Murphy, C, Murphy, K, Muscatello, C, Myers, C, Nagy, A, Nandipati, G, Navarro, M, Nave, F, Navratil, G, Nazikian, R, Neff, A, Neilson, G, Neiser, T, Neiswanger, W, Nelson, D, Nelson, A, Nespoli, F, Nguyen, R, Nguyen, L, Nguyen, X, Nichols, J, Nocente, M, Nogami, S, Noraky, S, Norausky, N, Nornberg, M, Nygren, R, Odstrcil, T, Ogas, D, Ogorman, T, Ohdachi, S, Ohtani, Y, Okabayashi, M, Okamoto, M, Olavson, L, Olofsson, E, Omullane, M, Oneill, R, Orlov, D, Orvis, W, Osborne, T, Pace, D, Canal, G, Martinez, A, Palacios, L, Pan, C, Pan, Q, Pandit, R, Pandya, M, Pankin, A, Park, Y, Park, J, Parker, S, Parks, P, Parsons, M, Patel, B, Pawley, C, Paz-Soldan, C, Peebles, W, Pelton, S, Perillo, R, Petty, C, Peysson, Y, Pierce, D, Pigarov, A, Pigatto, L, Piglowski, D, Pinches, S, Pinsker, R, Piovesan, P, Piper, N, Pironti, A, Pitts, R, Pizzo, J, Plank, U, Podesta, M, Poli, E, Poli, F, Ponce, D, Popovic, Z, Porkolab, M, Porter, G, Powers, C, Powers, S, Prater, R, Pratt, Q, Pusztai, I, Qian, J, Qin, X, Ra, O, Rafiq, T, Raines, T, Raman, R, Rauch, J, Raymond, A, Rea, C, Reich, M, Reiman, A, Reinhold, S, Reinke, M, Reksoatmodjo, R, Ren, Q, Ren, Y, Ren, J, Rensink, M, Renteria, J, Rhodes, T, Rice, J, Roberts, R, Robinson, J, Fernandez, P, Rognlien, T, Rosenthal, A, Rosiello, S, Rost, J, Roveto, J, Rowan, W, Rozenblat, R, Ruane, J, Rudakov, D, Ruiz, J, Rupani, R, Saarelma, S, Sabbagh, S, Sachdev, J, Saenz, J, Saib, S, Salewski, M, Salmi, A, Sammuli, B, Samuell, C, Sandorfi, A, Sang, C, Sarff, J, Sauter, O, Schaubel, K, Schmitz, L, Schmitz, O, Schneider, J, Schroeder, P, Schultz, K, Schuster, E, Schwartz, J, Sciortino, F, Scotti, F, Scoville, J, Seltzman, A, Seol, S, Sfiligoi, I, Shafer, M, Sharapov, S, Shen, H, Sheng, Z, Shepard, T, Shi, S, Shibata, Y, Shin, G, Shiraki, D, Shousha, R, Si, H, Simmerling, P, Sinclair, G, Sinha, J, Sinha, P, Sips, G, Sizyuk, T, Skinner, C, Sladkomedova, A, Slendebroek, T, Slief, J, Smirnov, R, Smith, J, Smith, S, Smith, D, Snipes, J, Snoep, G, Snyder, A, Snyder, P, Solano, E, Solomon, W, Song, J, Sontag, A, Soukhanovskii, V, Spendlove, J, Spong, D, Squire, J, Srinivasan, C, Stacey, W, Staebler, G, Stagner, L, Stange, T, Stangeby, P, Stefan, R, Stemprok, R, Stephan, D, Stillerman, J, Stoltzfus-Dueck, T, Stonecipher, W, Storment, S, Strait, E, Su, D, Sugiyama, L, Sun, Y, Sun, P, Sun, Z, Sun, A, Sundstrom, D, Sung, C, Sungcoco, J, Suttrop, W, Suzuki, Y, Suzuki, T, Svyatkovskiy, A, Swee, C, Sweeney, R, Sweetnam, C, Szepesi, G, Takechi, M, Tala, T, Tanaka, K, Tang, X, Tang, S, Tao, Y, Tao, R, Taussig, D, Taylor, T, Teixeira, K, Teo, K, Theodorsen, A, Thomas, D, Thome, K, Thorman, A, Thornton, A, Ti, A, Tillack, M, Timchenko, N, Tinguely, R, Tompkins, R, Tooker, J, De Sousa, A, Trevisan, G, Tripathi, S, Ochoa, A, Truong, D, Tsui, C, Turco, F, Turnbull, A, Umansky, M, Unterberg, E, Vaezi, P, Vail, P, Valdez, J, Valkis, W, Van Compernolle, B, Van Galen, J, Van Kampen, R, Van Zeeland, M, Verdoolaege, G, Vianello, N, Victor, B, Viezzer, E, Vincena, S, Wade, M, Waelbroeck, F, Wai, J, Wakatsuki, T, Walker, M, Wallace, G, Waltz, R, Wampler, W, Wang, L, Wang, H, Wang, Y, Wang, Z, Wang, G, Ward, S, Watkins, M, Watkins, J, Wehner, W, Wei, Y, Weiland, M, Weisberg, D, Welander, A, White, A, White, R, Wiesen, S, Wilcox, R, Wilks, T, Willensdorfer, M, Wilson, H, Wingen, A, Wolde, M, Wolff, M, Woller, K, Wolz, A, Wong, H, Woodruff, S, Wu, M, Wu, Y, Wukitch, S, Wurden, G, Xiao, W, Xie, R, Xing, Z, Xu, X, Xu, C, Xu, G, Yan, Z, Yang, X, Yang, S, Yokoyama, T, Yoneda, R, Yoshida, M, You, K, Younkin, T, Yu, J, Yu, M, Yu, G, Yuan, Q, Zaidenberg, L, Zakharov, L, Zamengo, A, Zamperini, S, Zarnstorff, M, Zeger, E, Zeller, K, Zeng, L, Zerbini, M, Zhang, L, Zhang, X, Zhang, R, Zhang, B, Zhang, J, Zhao, L, Zhao, B, Zheng, Y, Zheng, L, Zhu, B, Zhu, J, Zhu, Y, Zsutty, M, Zuin, M, Lawrence Livermore National Laboratory, Princeton Plasma Physics Laboratory, Princeton University, General Atomics, Max-Planck-Institut für Plasmaphysik, Imperial College London, National Institute for Fusion Science, Universidade de São Paulo, University of Texas at Austin, ITER, College of William and Mary, University of California Los Angeles, University of California San Diego, Columbia University, Massachusetts Institute of Technology, Oak Ridge National Laboratory, Eindhoven University of Technology, Oak Ridge Associated Universities, West Virginia University, University of Tennessee, Knoxville, National Research Council of Italy, Stony Brook University, Purdue University, University of Seville, University of Science and Technology of China, Carnegie Mellon University, Institute for Plasma Research, Peking University, University of California Davis, University of California Irvine, Commonwealth Fusion Systems, University of Liverpool, University of Illinois at Urbana-Champaign, University of Milan - Bicocca, Georgia Institute of Technology, Southwestern Institute of Physics, University of Toronto, Auburn University, Polytechnic University of Turin, Universidade Lisboa, Association CCFE, KTH Royal Institute of Technology, San Diego State University, Durham University, Lehigh University, Fusion and Plasma Physics, University of Washington, Department of Applied Physics, Sandia National Laboratories, Ghent University, Technical University of Denmark, CEA, University of Colorado Boulder, Harvard University, National Technical University of Athens, Coventry University, University of Stuttgart, Czech Academy of Sciences, Harvey Mudd College, Seoul National University, Donghua University, University of York, Dalian University of Technology, University of California Berkeley, Los Alamos National Laboratory, United States Department of Energy, University of British Columbia, Pacific Northwest National Laboratory, University of Wisconsin, Michigan State University, University of Strathclyde, Pennsylvania State University, Rensselaer Polytechnic Institute, University of Southern California, Chalmers University of Technology, University of Virginia, University of Naples Federico II, University of Oxford, VTT Technical Research Centre of Finland, National Institute of Technology, University of Connecticut, DIFFER, CIEMAT, Hanyang University, Brigham Young University, UiT The Arctic University of Norway, Australian National University, Russian Research Centre Kurchatov Institute, Forschungszentrum Jülich, Zhejiang University, The University of Tokyo, University of Michigan, Agenzia nazionale per le nuove tecnologie, l'energia e lo sviluppo economico sostenibile, Aalto-yliopisto, Aalto University, DIII-D Team, Complex Ionized Media, Elementary Processes in Gas Discharges, Applied Physics and Science Education, Science and Technology of Nuclear Fusion, and Control Systems Technology
- Subjects
Nuclear and High Energy Physics ,Tokamak ,Technology and Engineering ,DIII-D ,Nuclear engineering ,TOKAMAKS ,MITIGATION ,law.invention ,Plasma physics ,mitigation ,law ,plasma physic ,tokamak ,Physics ,Core-edge integration ,Basis (linear algebra) ,plasma physics ,core-edge integration ,scenarios ,Fusion power ,Condensed Matter Physics ,SCENARIOS ,fusion energy ,Fusion energy - Abstract
Funding Information: This material is based upon work supported by the US Department of Energy, Office of Science, Office of Fusion Energy Sciences, using the DIII-D National Fusion Facility, a DOE Office of Science user facility, under Awards DE-FC02-04ER54698 and DE-AC52-07NA27344. Publisher Copyright: © 2022 IAEA, Vienna. DIII-D physics research addresses critical challenges for the operation of ITER and the next generation of fusion energy devices. This is done through a focus on innovations to provide solutions for high performance long pulse operation, coupled with fundamental plasma physics understanding and model validation, to drive scenario development by integrating high performance core and boundary plasmas. Substantial increases in off-axis current drive efficiency from an innovative top launch system for EC power, and in pressure broadening for Alfven eigenmode control from a co-/counter-I p steerable off-axis neutral beam, all improve the prospects for optimization of future long pulse/steady state high performance tokamak operation. Fundamental studies into the modes that drive the evolution of the pedestal pressure profile and electron vs ion heat flux validate predictive models of pedestal recovery after ELMs. Understanding the physics mechanisms of ELM control and density pumpout by 3D magnetic perturbation fields leads to confident predictions for ITER and future devices. Validated modeling of high-Z shattered pellet injection for disruption mitigation, runaway electron dissipation, and techniques for disruption prediction and avoidance including machine learning, give confidence in handling disruptivity for future devices. For the non-nuclear phase of ITER, two actuators are identified to lower the L-H threshold power in hydrogen plasmas. With this physics understanding and suite of capabilities, a high poloidal beta optimized-core scenario with an internal transport barrier that projects nearly to Q = 10 in ITER at ∼8 MA was coupled to a detached divertor, and a near super H-mode optimized-pedestal scenario with co-I p beam injection was coupled to a radiative divertor. The hybrid core scenario was achieved directly, without the need for anomalous current diffusion, using off-axis current drive actuators. Also, a controller to assess proximity to stability limits and regulate β N in the ITER baseline scenario, based on plasma response to probing 3D fields, was demonstrated. Finally, innovative tokamak operation using a negative triangularity shape showed many attractive features for future pilot plant operation.
- Published
- 2022
- Full Text
- View/download PDF
220. Commentaire de l'article « rupture séromusculeuse de l'œsophage après vomissement : une cause rare d'hémothorax » de F.-A. Hunald, vol 131, no 3
- Author
-
Giuly, J. and Nguyen, R.
- Published
- 2006
- Full Text
- View/download PDF
221. Seasonal abundance and temperature sensitivity of sugarcane delphacid (Homoptera: Delphacidae)
- Author
-
Nguyen, R., Cherry, R. H., and Sosa, Jr., O.
- Subjects
TEMPERATURE - Published
- 1986
222. Endoscopic ultrasound (EUS) guided fine needle aspiration (FNA) of gastrointestinal (GI) tract lesions: A multi-center assessment of accuracy, complication rate and technical competence
- Author
-
Catalano, M.F., Hoffman, B., Bhutani, M., Nguyen, R., Wassef, W., Erickson, E., Scheiman, J., VanDam, J., Harada, N., Aliperti, G., Gress, F., and Wiersema, M.
- Published
- 1997
- Full Text
- View/download PDF
223. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
- Author
-
Dimitrios Farmakiotis, Susie Owenby, Arturo Loaiza-Bonilla, Mansi R. Shah, Matthew Puc, Vadim S. Koshkin, Ahmad Daher, Prakash Peddi, Cameron Rink, Heloisa P. Soares, Eneida R. Nemecek, Mehmet Asim Bilen, Sanjay Mishra, Lidia Schapira, Amit Verma, Ali Raza Khaki, Chih-Yuan Hsu, Sandy DiLullo, Mark Bonnen, Jeanna Knoble, Carla Casulo, Umit Topaloglu, Jorge A. Garcia, Geoffrey Shouse, Praveen Vikas, Clarke A. Low, Archana Ajmera, George D. Demetri, Leyre Zubiri, Grace Glace, Shannon K. McWeeney, Susan Yackzan, Pamela C Egan, Rachel P. Rosovsky, Salvatore Del Prete, Anthony P. Gulati, Lane R. Rosen, Andy Futreal, Merry Jennifer Markham, Sabitha Prabhakaran, Alicia K. Morgans, Sarah Nagle, Lisa Weissmann, Albert C. Yeh, Ziad Bakouny, Stephanie Berg, David Gill, Marcus Messmer, Ryan Nguyen, Terence Duane Rhodes, Vikram M. Narayan, Matthew D. Galsky, Arielle Elkrief, Lori J. Rosenstein, Roy S. Herbst, Justin Shaya, Thorvardur R. Halfdanarson, Douglas B. Johnson, Orestis A. Panagiotou, Sanjay G. Revankar, Toni K. Choueiri, Yu Shyr, Fiona Busser, Kaitlin M. Kelleher, Nicole M. Kuderer, Paul L. Weinstein, Anup Kasi, Grace Shaw, Adam J. Olszewski, Catherine Curran, Samuel M. Rubinstein, Angelo Cabal, Michael H. Bar, John F. Deeken, Vivek Subbiah, Abdul Hai Mansoor, Hina Khan, Rana R. McKay, Catherine Stratton, Saurabh Dahiya, Marc A. Rovito, John Philip, Sanjay Shete, Oscar K. Serrano, Julie Fu, Daniel W. Bowles, Candice Schwartz, Tian Zhang, Pier Vitale Nuzzo, Eric H. Bernicker, Wenxin Xu, Genevieve M. Boland, Sarah Wall, Babar Bashir, Solange Peters, Neeta K. Venepalli, Sandeep H. Mashru, William A. Wood, Anne H. Angevine, Mary F. Mulcahy, Gilberto Lopes, Justin F. Gainor, Jessica Hawley, Monika Joshi, Christopher R. Friese, Navid Hafez, Heather H. Nelson, Gregory J. Riely, Jordan Kharofa, Nilo Azad, Chintan Shah, Gerald Batist, Mary Salazar, Rosemary Zacks, Alice Zhou, Lawrence E. Feldman, Paul Fu, Gary H. Lyman, Nathaniel Bouganim, John A. Steinharter, Shilpa Gupta, Matthias Weiss, Peter Paul Yu, Susan Van Loon, Jamie Stratton, Karen Vega-Luna, Tyler Masters, Christopher Lemmon, Aakash Desai, Bryan A. Faller, Jessica M. Clement, Zhuoer Xie, Keith Stockerl-Goldstein, Corrie A. Painter, Gabrielle Bouchard, Rulla M. Tamimi, Daruka Mahadevan, Rimma Belenkaya, Jill S. Barnholtz-Sloan, Jarushka Naidoo, Amelie G. Ramirez, Philip E. Lammers, Elizabeth A. Griffiths, Michael J. Gurley, X. Li, Jonathan Riess, Syed A. Ahmad, Daniel Blake Flora, Salma K. Jabbour, Jared D. Acoba, Neeraj Agarwal, Ang Li, Sarah Mushtaq, Firas Wehbe, Tanios Bekaii-Saab, Donald C. Vinh, Emily Hsu, Ryan Monahan, Petros Grivas, Harry Menon, John M. Nakayama, Janice M. Mehnert, Elizabeth Marie Wulff-Burchfield, Sara Matar, Paul E. Oberstein, Mary M. Pasquinelli, Axel Grothey, Jack West, John C. Leighton, Dawn L. Hershman, Leslie A. Fecher, Aditya Bardia, Sumit A. Shah, Barbara Logan, Kerry L. Reynolds, Michael A. Thompson, Robert L. Rice, Erin Cook, Trisha Wise-Draper, Christine Bestvina, Daniel Castellano, Paolo Caimi, K. M.Steve Lo, Ruben A. Mesa, Maheen Z. Abidi, Alvaro G. Menendez, Daniel G. Stover, Colleen Lewis, Bertrand Routy, Deborah B. Doroshow, Carmen C. Solorzano, M. Wasif Saif, Rohit Bishnoi, Michael Glover, David D. Chism, Briana Barrow, Christopher McNair, Dimpy P. Shah, Erin A. Gillaspie, Andrea J. Zimmer, Andrew Schmidt, Jessica K. Altman, Michelle Marcum, Rawad Elias, Balazs Halmos, Karen Stauffer, Gayathri Nagaraj, Ardaman Shergill, Mark E. Dailey, Catherine Handy Marshall, Pramod K. Srivastava, Shuchi Gulati, Alokkumar Jha, Mateo Bover Larroya, Mark A. Lewis, Young Soo Rho, James L. Chen, Eli Van Allen, Julie Tsu Yu Wu, Antonio Giordano, Amit Kulkarni, Joerg Rathmann, Donna R. Rivera, Narjust Duma, Maryam B. Lustberg, Theresa M. Carducci, Jeremy L. Warner, Elizabeth Robilotti, Patricia LoRusso, Rohit Jain, Amit Sanyal, Nizar M. Tannir, Kent Hoskins, Nathan A. Pennell, Brian I. Rini, Suki Subbiah, COVID-19 and Cancer Consortium, Abidi, M., Acoba, J.D., Agarwal, N., Ahmad, S., Ajmera, A., Altman, J., Angevine, A.H., Azad, N., Bar, M.H., Bardia, A., Barnholtz-Sloan, J., Barrow, B., Bashir, B., Belenkaya, R., Berg, S., Bernicker, E.H., Bestvina, C., Bishnoi, R., Boland, G., Bonnen, M., Bouchard, G., Bowles, D.W., Busser, F., Cabal, A., Caimi, P., Carducci, T., Casulo, C., Chen, J.L., Clement, J.M., Chism, D., Cook, E., Curran, C., Daher, A., Dailey, M., Dahiya, S., Deeken, J., Demetri, G.D., DiLullo, S., Duma, N., Elias, R., Faller, B., Fecher, L.A., Feldman, L.E., Friese, C.R., Fu, P., Fu, J., Futreal, A., Gainor, J., Garcia, J., Gill, D.M., Gillaspie, E.A., Giordano, A., Glace, M.G., Grothey, A., Gulati, S., Gurley, M., Halmos, B., Herbst, R., Hershman, D., Hoskins, K., Jain, R.K., Jabbour, S., Jha, A., Johnson, D.B., Joshi, M., Kelleher, K., Kharofa, J., Khan, H., Knoble, J., Koshkin, V.S., Kulkarni, A.A., Lammers, P.E., Leighton, J.C., Lewis, M.A., Li, X., Li, A., Lo, KMS, Loaiza-Bonilla, A., LoRusso, P., Low, C.A., Lustberg, M.B., Mahadevan, D., Mansoor, A.H., Marcum, M., Markham, M.J., Handy Marshall, C., Mashru, S.H., Matar, S., McNair, C., McWeeney, S., Mehnert, J.M., Menendez, A., Menon, H., Messmer, M., Monahan, R., Mushtaq, S., Nagaraj, G., Nagle, S., Naidoo, J., Nakayama, J.M., Narayan, V., Nelson, H.H., Nemecek, E.R., Nguyen, R., Nuzzo, P.V., Oberstein, P.E., Olszewski, A.J., Owenby, S., Pasquinelli, M.M., Philip, J., Prabhakaran, S., Puc, M., Ramirez, A., Rathmann, J., Revankar, S.G., Rho, Y.S., Rhodes, T.D., Rice, R.L., Riely, G.J., Riess, J., Rink, C., Robilotti, E.V., Rosenstein, L., Routy, B., Rovito, M.A., Saif, M.W., Sanyal, A., Schapira, L., Schwartz, C., Serrano, O., Shah, M., Shah, C., Shaw, G., Shergill, A., Shouse, G., Soares, H.P., Solorzano, C.C., Srivastava, P.K., Stauffer, K., Stover, D.G., Stratton, J., Stratton, C., Subbiah, V., Tamimi, R., Tannir, N.M., Topaloglu, U., Van Allen, E., Van Loon, S., Vega-Luna, K., Venepalli, N., Verma, A.K., Vikas, P., Wall, S., Weinstein, P.L., Weiss, M., Wise-Draper, T., Wood, W.A., Xu, W.V., Yackzan, S., Zacks, R., Zhang, T., Zimmer, A.J., and West, J.
- Subjects
Prognostic variable ,medicine.medical_specialty ,business.industry ,Cancer ,General Medicine ,Odds ratio ,Aged ,Antiviral Agents/therapeutic use ,Azithromycin/therapeutic use ,Betacoronavirus ,Cause of Death ,Comorbidity ,Coronavirus Infections/drug therapy ,Coronavirus Infections/epidemiology ,Coronavirus Infections/mortality ,Databases, Factual ,Female ,Humans ,Hydroxychloroquine/therapeutic use ,Male ,Middle Aged ,Neoplasms/epidemiology ,Neoplasms/mortality ,Neoplasms/therapy ,Pandemics ,Pneumonia, Viral/drug therapy ,Pneumonia, Viral/epidemiology ,Pneumonia, Viral/mortality ,Prognosis ,Risk Factors ,030204 cardiovascular system & hematology ,medicine.disease ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,Cohort ,Clinical endpoint ,Medicine ,030212 general & internal medicine ,business ,Cause of death ,Cohort study - Abstract
Summary Background Data on patients with COVID-19 who have cancer are lacking. Here we characterise the outcomes of a cohort of patients with cancer and COVID-19 and identify potential prognostic factors for mortality and severe illness. Methods In this cohort study, we collected de-identified data on patients with active or previous malignancy, aged 18 years and older, with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection from the USA, Canada, and Spain from the COVID-19 and Cancer Consortium (CCC19) database for whom baseline data were added between March 17 and April 16, 2020. We collected data on baseline clinical conditions, medications, cancer diagnosis and treatment, and COVID-19 disease course. The primary endpoint was all-cause mortality within 30 days of diagnosis of COVID-19. We assessed the association between the outcome and potential prognostic variables using logistic regression analyses, partially adjusted for age, sex, smoking status, and obesity. This study is registered with ClinicalTrials.gov, NCT04354701, and is ongoing. Findings Of 1035 records entered into the CCC19 database during the study period, 928 patients met inclusion criteria for our analysis. Median age was 66 years (IQR 57–76), 279 (30%) were aged 75 years or older, and 468 (50%) patients were male. The most prevalent malignancies were breast (191 [21%]) and prostate (152 [16%]). 366 (39%) patients were on active anticancer treatment, and 396 (43%) had active (measurable) cancer. At analysis (May 7, 2020), 121 (13%) patients had died. In logistic regression analysis, independent factors associated with increased 30-day mortality, after partial adjustment, were: increased age (per 10 years; partially adjusted odds ratio 1·84, 95% CI 1·53–2·21), male sex (1·63, 1·07–2·48), smoking status (former smoker vs never smoked: 1·60, 1·03–2·47), number of comorbidities (two vs none: 4·50, 1·33–15·28), Eastern Cooperative Oncology Group performance status of 2 or higher (status of 2 vs 0 or 1: 3·89, 2·11–7·18), active cancer (progressing vs remission: 5·20, 2·77–9·77), and receipt of azithromycin plus hydroxychloroquine (vs treatment with neither: 2·93, 1·79–4·79; confounding by indication cannot be excluded). Compared with residence in the US-Northeast, residence in Canada (0·24, 0·07–0·84) or the US-Midwest (0·50, 0·28–0·90) were associated with decreased 30-day all-cause mortality. Race and ethnicity, obesity status, cancer type, type of anticancer therapy, and recent surgery were not associated with mortality. Interpretation Among patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments. Funding American Cancer Society, National Institutes of Health, and Hope Foundation for Cancer Research.
- Published
- 2020
- Full Text
- View/download PDF
224. Reimagining transcultural identity: a case study of field experiences for international preservice teachers
- Author
-
Ruth Geer, R. Reid-Nguyen, M. Mills-Bayne, Hannah Soong, B. Lucas, L. Kerkham, Soong, H, Kerkham, L, Reid-Nguyen, R, Lucas, B, Geer, R, and Mills-Bayne, MM
- Subjects
field experiences ,Field (Bourdieu) ,05 social sciences ,050401 social sciences methods ,050301 education ,Identity (social science) ,Gender studies ,Teacher education ,Education ,International education ,0504 sociology ,Cultural diversity ,international preservice teachers ,Sociology ,cultural diversity ,0503 education ,identity ,transcultural ,teacher education - Abstract
Around the world, over 5.3 million students were engaged in international education in 2017. In Australia, international students made a significant contribution to the country’s economy and its society. However, there is a paucity in theory and of empirical research on the effects of field experience on international preservice teachers (IPSTs). Addressing this gap, the paper contributes to an understanding of the changes to the identities of IPSTs engaged in field experiences. Drawing on a single case study of a group of first-year IPSTs undertaking a non-assessed field experience, the concept of ‘transcultural’ is employed to understand the links between culture, place and identity that the cohort experience in the host education sites. This paper shows the emergence of how IPSTs understand how children learn and its connection with pedagogy as part of them becoming transcultural. While this study occurs before COVID-19, it argues for shared responsibility between universities, education sites and teachers to enable the transcultural meanings to be established within the field experience, thereby creating inclusive conditions central to IPSTs’ contribution to the existing cultural and linguistic diversities in education settings. This is even more vital under the changed circumstances of COVID-19. Refereed/Peer-reviewed
- Published
- 2021
225. Exploring the expressed concerns of bipolar disorder patients: Directions for psychosocial targets of treatment
- Author
-
⁎, V., Parikh, S., Nguyen, R., Pezeseng, M., and Anderson, B.
- Published
- 2010
- Full Text
- View/download PDF
226. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial
- Author
-
Pivot, Xavier, Romieu, Gilles, Debled, Marc, Pierga, Jean-Yves, Kerbrat, Pierre, Bachelot, Thomas, Lortholary, Alain, Espié, Marc, Fumoleau, Pierre, Serin, Daniel, Jacquin, Jean-Philippe, Jouannaud, Christelle, Rios, Maria, Abadie-Lacourtoisie, Sophie, Venat-Bouvet, Laurence, Cany, Laurent, Catala, Stéphanie, Khayat, David, Gambotti, Laetitia, Pauporté, Iris, Faure-Mercier, Céline, Paget-Bailly, Sophie, Henriques, Julie, Grouin, Jean Marie, Centre Paul Strauss, CRLCC Paul Strauss, CRLCC Val d'Aurelle - Paul Lamarque, Institut Bergonié [Bordeaux], UNICANCER, Institut Curie [Paris], Université Paris Descartes - Paris 5 (UPD5), CRLCC Eugène Marquis (CRLCC), Centre Léon Bérard [Lyon], Centre Catherine-de-Sienne [Nantes] (CCS), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Sainte Catherine [Avignon], Institut de Cancérologie Lucien Neuwirth, CHU Saint-Etienne, CRLCC Jean Godinot, Institut Jean Godinot [Reims], Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), Institut de Cancérologie de l'Ouest [Angers/Nantes] (UNICANCER/ICO), CHU Limoges, Clinique Francheville [Périgueux], CHU Saint-Pierre, Clinique Bizet [Pais], Institut national du cancer [Boulogne] (INCA), Ligue Nationale Contre le Cancer - Paris, Ligue Nationale Contre le Cancer (LNCC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Unité de biostatistiques [CHU Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), The French National Cancer Institute, PHARE trial investigators: C Piprot, L Cals, L Chaigneau, F Demarchi, T N'Guyen, U Stein, C Villanueva, J L Bréau, A K Chouahnia, P Saintigny, F Boué, P deSaint-Hilaire, I Guimont, N Grossat, B Valenza, E Lévy, J Médioni, C Delbaldo, J Grenier, D Pouessel, S Lavau-Denès, C Falandry, C Fournel-Fédérico, G Freyer, S Tartas, V Trillet-Lenoir, F Bons, G Auclerc, S Chièze, N Raban, C Tournigand, S Trager-Maury, G Bousquet, C Cuvier, S Giacchetti, A Hocini, C LeMaignan, J L Misset, D Avenin, C Beerblock, J Gligorov, P Rivera, H Roché, P Bougnoux, N Hajjaji, O Capitain, R Delva, P Maillart, P Soulié, H Bonnefoi, M Durand, N Madranges, L Mauriac, P Chollet, A F Dillies, X Durando, J P Ferrière, C Mouret-Reynier, J M Nabholtz, I Van Praagh, P Cottu, V Diéras, A Durieux, M Galotte, V Girre, S Henry, I Iurisci, M Jouve, V Laurence, L Mignot, S Piperno-Neumann, P Tresca, B Coudert, E Ferrant, F Mayer, A C Vanneuville, J Bonneterre, V Servent, L Vanlemmens, P Vennin, J P Guastalla, P Biron, L Dupuy-Brousseau, L Lancry, I Ray-Coquard, P Rebattu, O Trédan, J M Extra, F Rousseau, C Tarpin, M Fabbro, E Luporsi, L Uwer, B Weber, D Berton-Rigaud, E Bourbouloux, M Campone, J M Ferrero, P Follana, R Largillier, V Mari, B Costa, H Curé, J C Eymard, N Jovenin, D Lebrun, J Meunier, G Yazbek, D Gedoin, B Laguerre, C Lefeuvre, E Vauléon, A Chevrier, C Guillemet, M Leheurteur, O Rigal, I Tennevet, C Veyret, E Brain, M Guiterrez, F Mefti-Lacheraf, T Petit, F Dalenc, L Gladieff, H Roché, F André, S Delaloge, J Domont, J Ezenfis, M Spielmann, P Guillet, V Boulanger, J Provençal, L Stefani, C Alliot, D Ré, C Bellaiche-Miccio, G Boutan-Laroze, R Vanica, P Dion, A Hocini, G Sadki-Benaoudia, A Marti, A L Villing, B Slama, J L Dutel, S Nguyen, R Saad, O Arsène, Z Merad-Boudia, H Orfeuvre, J Egreteau, M J Goudier, R Lamy, B Leduc, C Sarda, B Salles, C Agostini, I Cauvin, A Dufresne, M Mangold, S Lebouvier-Sadot, B Audhuy, J C Barats, S Cluet-Dennetière, D Zylberait, G Netter, L Gautier-Felizot, I Cojean-Zelek, A Plantade, S Vignot, E Guardiola, P Marti, I deHartingh, R Diab, A Dietmann, S Ruck, C Portois, E Guardiola, S Oddou-Lagranière, F Campos-Gazeau, A Bourcier, F Priou, J F Geay, D Mayeur, P Gabez, R ElAmarti, M Combe, J Ezenfis, P Raichon-Patru, P Amsalhem, J Dauba, D Paraiso, F Guinet, B Duvert, M Litor, F Kara-Slimane, A Bichoffe, N Denizon, J Meunier, P Soyer, F Morvan, S Van-Hulst, L Vincent, C Alleaume, P Ibanez-Martin, A Youssef, Z Tadrist, E Carola, C Pourny, J F Toccanier, N Al-Aukla, K Mahour-Bacha, J Salvat, L Cals, P Nouyrigat, S Clippe, M C Gouttebel, L Vedrine, G Clavreul, O Collard, D Mille, Y Goubely, J Grenier, R Hervé, S Kirscher, F Plat, V Delecroix, V Ligeza-Poisson, D Coeffic, L Dupuy-Brousseau, D Fric, C Garnier, C Leyronnas, T Kreitman, R Largillier, E Teissier, P Martin, S Rohart deCordoue, C ElKouri, J F Ramée, C Laporte, O Bernard, T Altwegg, A Darut-Jouve, J P Dujols, F Darloy, C Giraud, V Pottier-Kyndt, N Achour, S Drony, M Moriceau, C Sarrazin, J C Legueul, J Mandet, D Besson, A C Hardy-Bessard, J Cretin, P Houyau, E Achille, D Genêt, H Thévenot, A Moran-Ribon, J M Pavlovitch, P Ardisson, I Moullet, B Couderc, V Fichet, F Burki, A Auliard, C B Levaché, G Auclerc, P Cailleux, F Schaeffer, N Albin, D Sévin-Robiche, J Domas, S Ellis, P Montcuquet, G A Baumont, M Bégue, S Gréget, J L Ratoanina, A Vanoli, C Bielsa, M Bonichon-Lamichhane, D Jaubert, H Laharie-Mineur, L Alcaraz, J Cretin, E Legouffe, H Bourgeois, G Cartron, F Denis, O Dupuis, G Ganem, S Roche-Forestier, L Delzenne, E Chirat, J L Baticle, E Béguier, S Jacquot, E Janssen, H Lauché, A LeRol, J P Chantelard, G A L'Helgoualc'h, E C Antoine, A Kanoui, J F Llory, J M Vannetzel, J Vignoud, C Bruna, T Facchini, K Moutel-Corviole, A Voloch, A Ghoul, D Loiseau, K Mahour-Bacha, N Barbet, N Dohollou, K Yakendji, CCSD, Accord Elsevier, and Ligue Nationnale Contre le Cancer
- Subjects
[SDV.CAN] Life Sciences [q-bio]/Cancer ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,skin and connective tissue diseases - Abstract
International audience; Background: In 2013, the interim analysis of the Protocol for Herceptin as Adjuvant therapy with Reduced Exposure (PHARE) trial could not show that 6 months of adjuvant trastuzumab was non-inferior to 12 months. Here, we report the planned final analysis based on the prespecified number of occurring events.Methods: PHARE is an open-label, phase 3, non-inferiority randomised trial of patients with HER2-positive early breast cancer comparing 6 months versus 12 months of trastuzumab treatment concomitant with or following standard neoadjuvant or adjuvant chemotherapy. The study was undertaken in 156 centres in France. Eligible patients were women aged 18 years or older with non-metastatic, operable, histologically confirmed adenocarcinoma of the breast and either positive axillary nodes or negative axillary nodes but a tumour of at least 10 mm. Participants must have received at least four cycles of a chemotherapy for this breast cancer and have started receiving adjuvant trastuzumab-treatment. Eligible patients were randomly assigned to either 6 months or 12 months of trastuzumab therapy duration between the third and sixth months of adjuvant trastuzumab. The randomisation was stratified by concomitant or sequential treatment with chemotherapy, oestrogen receptor status, and centre. The primary objective was non-inferiority in the intention-to-treat population in the 6-month group in terms of disease-free survival with a prespecified hazard margin of 1·15. This trial is registered with ClinicalTrials.gov, number NCT00381901.Findings: 3384 patients were enrolled and randomly assigned to either 12 months (n=1691) or 6 months (n=1693) of adjuvant trastuzumab. One patient in the 12-month group and three patients in the 6-month group were excluded, so 1690 patients in each group were included in the intention-to-treat analysis. At a median follow-up of 7·5 years (IQR 5·3-8·8), 704 events relevant to disease-free survival were observed (345 [20·4%] in the 12-month group and 359 [21·2%] in the 6-month group). The adjusted hazard ratio for disease-free survival in the 12-month group versus the 6-month group was 1·08 (95% CI 0·93-1·25; p=0·39). The non-inferiority margin was included in the 95% CI. No differences in effects pertaining to trastuzumab duration were found in any of the subgroups. After the completion of trastuzumab treatment, rare adverse events occurred over time and the safety analysis remained similar to the previously published report. In particular, we found no change in the cardiac safety comparison, and only three additional cases in which the left ventricular ejection fraction decreased to less than 50% have been reported in the 12-month group.Interpretation: The PHARE study did not show the non-inferiority of 6 months versus 12 months of adjuvant trastuzumab. Hence, adjuvant trastuzumab standard duration should remain 12 months.
- Published
- 2019
227. DIII-D research towards establishing the scientific basis for future fusion reactors
- Author
-
L. Abadie, T. W. Abrams, J. Ahn, T. Akiyama, P. Aleynikov, J. Allcock, E. O. Allen, S. Allen, J. P. Anderson, A. Ashourvan, M. E. Austin, J. Bak, K. K. Barada, N. Barbour, L. Bardoczi, J. Barr, J. L. Barton, E. M. Bass, D. Battaglia, L. R. Baylor, J. Beckers, E. A. Belli, J. W. Berkery, N. Bertelli, J. M. Bialek, J. A. Boedo, R. L. Boivin, P. T. Bonoli, A. Bortolon, M. D. Boyer, R. E. Brambila, B. Bray, D. P. Brennan, A. R. Briesemeister, S. A. Bringuier, M. W. Brookman, D. L. Brower, B. R. Brown, W. D. Brown, D. Buchenauer, M. G. Burke, K. H. Burrell, J. Butt, R. J. Buttery, I. Bykov, J. M. Candy, J. M. Canik, N. M. Cao, L. Carbajal Gomez, L. C. Carlson, T. N. Carlstrom, T. A. Carter, W. Cary, L. Casali, M. Cengher, V. S. Chan, B. Chen, J. Chen, M. Chen, R. Chen, Xi Chen, W. Choi, C. Chrobak, C. Chrystal, R. M. Churchill, M. Cianciosa, C. F. Clauser, M. Clement, J. Coburn, C. S. Collins, A. W. Cooper, B. M. Covele, J. W. Crippen, N. A. Crocker, B. J. Crowley, A. Dal Molin, E. M. Davis, J. S. deGrassie, C. A. del-Castillo-Negrete, L. F. Delgado-Aparicio, A. Diallo, S. J. Diem, R. Ding, S. Ding, W. Ding, J. L. Doane, D. C. Donovan, J. Drake, D. Du, H. Du, X. Du, V. Duarte, J. D. Duran, N. W. Eidietis, D. Elder, D. Eldon, W. Elwasif, T. E. Ely, K. M. Eng, K. Engelhorn, D. Ennis, K. Erickson, D. R. Ernst, T. E. Evans, M. E. Fenstermacher, N. M. Ferraro, J. R. Ferron, D. F. Finkenthal, P. A. Fisher, B. Fishler, S. M. Flanagan, J. A. Fooks, L. Frassinetti, H. G. Frerichs, Y. Fu, T. Fulop, Q. Gao, F. Garcia, A. M. Garofalo, A. Gattuso, L. Giacomelli, E. M. Giraldez, C. Giroud, F. Glass, P. Gohil, X. Gong, Y. A. Gorelov, R. S. Granetz, D. L. Green, C. M. Greenfield, B. A. Grierson, R. J. Groebner, W. H. Grosnickle, M. Groth, H. J. Grunloh, H. Y. Guo, W. Guo, J. Guterl, R. C. Hager, S. Hahn, F. D. Halpern, H. Han, M. J. Hansink, J. M. Hanson, J. Harris, S. R. Haskey, D. R. Hatch, W. W. Heidbrink, J. Herfindal, D. N. Hill, M. D. Hill, E. T. Hinson, C. T. Holcomb, C. G. Holland, L. D. Holland, E. M. Hollmann, A. M. Holm, R. Hong, M. Hoppe, S. Houshmandyar, J. Howard, N. T. Howard, Q. Hu, W. Hu, H. Huang, J. Huang, Y. Huang, G. A. Hughes, J. Hughes, D. A. Humphreys, A. W. Hyatt, K. Ida, V. Igochine, Y. In, S. Inoue, A. Isayama, R. C. Isler, V. A. Izzo, M. R. Jackson, A. E. Jarvinen, Y. Jeon, H. Ji, X. Jian, R. Jimenez, C. A. Johnson, I. Joseph, D. N. Kaczala, D. H. Kaplan, J. Kates-Harbeck, A. G. Kellman, D. H. Kellman, C. E. Kessel, K. Khumthong, C. C. Kim, H. Kim, J. Kim, K. Kim, S. H. Kim, W. Kimura, J. R. King, A. Kirk, K. Kleijwegt, M. Knolker, A. Kohn, E. Kolemen, M. Kostuk, G. J. Kramer, P. Kress, D. M. Kriete, R. J. La Haye, F. M. Laggner, H. Lan, M. J. Lanctot, R. Lantsov, L. L. Lao, C. J. Lasnier, C. Lau, K. Law, D. Lawrence, J. Le, R. L. Lee, M. Lehnen, R. Leon, A. W. Leonard, M. Lesher, J. A. Leuer, G. Li, K. Li, K. T. Liao, Z. Lin, C. Liu, F. Liu, Y. Liu, Z. Liu, S. Loch, N. C. Logan, J. M. Lohr, J. Lore, T. C. Luce, N. C. Luhmann, R. Lunsford, C. Luo, Z. Luo, L. Lupin-Jimenez, A. Lvovskiy, B. C. Lyons, X. Ma, R. Maingi, M. A. Makowski, P. Mantica, M. Manuel, M. W. Margo, A. Marinoni, E. Marmar, W. C. Martin, R. L. Masline, G. K. Matsunaga, D. M. Mauzey, P. S. Mauzey, J. T. Mcclenaghan, G. R. Mckee, A. G. Mclean, H. S. Mclean, E. Meier, S. J. Meitner, J. E. Menard, O. Meneghini, G. Merlo, W. H. Meyer, D. C. Miller, W. J. Miller, C. P. Moeller, K. J. Montes, M. A. Morales, S. Mordijck, A. Moser, R. A. Moyer, S. A. Muller, S. Munaretto, M. Murakami, C. J. Murphy, C. M. Muscatello, C. E. Myers, A. Nagy, G. A. Navratil, R. M. Nazikian, A. L. Neff, T. F. Neiser, A. Nelson, P. Nguyen, R. Nguyen, J. H. Nichols, M. Nocente, R. E. Nygren, R. C. O'Neill, T. Odstrcil, S. Ohdachi, M. Okabayashi, E. Olofsson, M. Ono, D. M. Orlov, T. H. Osborne, N. A. Pablant, D. C. Pace, R. R. Paguio, A. Pajares Martinez, C. Pan, A. Pankin, J. M. Park, J. Park, Y. Park, C. T. Parker, S. E. Parker, P. B. Parks, C. J. Pawley, C. A. Paz-Soldan, W. A. Peebles, B. G. Penaflor, T. W. Petrie, C. C. Petty, Y. Peysson, A. Y. Pigarov, D. A. Piglowski, R. I. Pinsker, P. Piovesan, N. Piper, R. A. Pitts, J. D. Pizzo, M. L. Podesta, F. M. Poli, D. Ponce, M. Porkolab, G. D. Porter, R. Prater, J. Qian, O. Ra, T. Rafiq, R. Raman, C. Rand, G. C. Randall, J. M. Rauch, C. Rea, M. L. Reinke, J. Ren, Q. Ren, Y. Ren, T. L. Rhodes, J. Rice, T. D. Rognlien, J. C. Rost, W. L. Rowan, D. L. Rudakov, A. Salmi, B. S. Sammuli, C. M. Samuell, A. M. Sandorfi, C. Sang, O. J. Sauter, D. P. Schissel, L. Schmitz, O. Schmitz, E. J. Schuster, J. T. Scoville, A. Seltzman, I. Sfiligoi, M. Shafer, H. Shen, T. Shi, D. Shiraki, H. Si, D. R. Smith, S. P. Smith, J. A. Snipes, P. B. Snyder, E. R. Solano, W. M. Solomon, A. C. Sontag, V. A. Soukhanovskii, D. A. Spong, W. M. Stacey, G. M. Staebler, L. Stagner, B. Stahl, P. C. Stangeby, T. J. Stoltzfus-Dueck, D. P. Stotler, E. J. Strait, D. Su, L. E. Sugiyama, A. A. Sulyman, Y. Sun, C. Sung, W. A. Suttrop, Y. Suzuki, A. Svyatkovskiy, R. M. Sweeney, S. Taimourzadeh, M. Takechi, T. Tala, H. Tan, S. Tang, X. Tang, D. Taussig, G. Taylor, N. Z. Taylor, T. S. Taylor, A. Teklu, D. M. Thomas, M. B. Thomas, K. E. Thome, A. R. Thorman, R. A. Tinguely, B. J. Tobias, J. F. Tooker, H. Torreblanca, A. Torrezan De Sousa, G. L. Trevisan, D. Truong, F. Turco, A. D. Turnbull, E. A. Unterberg, P. Vaezi, P. J. Vail, M. A. Van Zeeland, M. Velasco Enriquez, M. C. Venkatesh, B. S. Victor, F. Volpe, M. R. Wade, M. L. Walker, J. R. Wall, G. M. Wallace, R. E. Waltz, G. Wang, H. Wang, Y. Wang, Z. Wang, F. Wang, S. H. Ward, J. G. Watkins, M. Watkins, W. P. Wehner, M. Weiland, D. B. Weisberg, A. S. Welander, A. E. White, R. B. White, D. Whyte, T. A. Wijkamp, R. Wilcox, T. Wilks, H. R. Wilson, A. Wingen, E. Wolfe, M. Wu, W. Wu, S. J. Wukitch, T. Xia, N. Xiang, B. Xiao, R. Xie, G. Xu, H. Xu, X. Xu, Z. Yan, Q. Yang, X. Yang, M. Yoshida, G. Yu, J. H. Yu, M. Yu, S. A. Zamperini, L. Zeng, B. Zhao, D. Zhao, H. Zhao, Y. Zhao, Y. Zhu, B. Zywicki, Abadie, L, Abrams, T, Ahn, J, Akiyama, T, Aleynikov, P, Allcock, J, Allen, E, Allen, S, Anderson, J, Ashourvan, A, Austin, M, Bak, J, Barada, K, Barbour, N, Bardoczi, L, Barr, J, Barton, J, Bass, E, Battaglia, D, Baylor, L, Beckers, J, Belli, E, Berkery, J, Bertelli, N, Bialek, J, Boedo, J, Boivin, R, Bonoli, P, Bortolon, A, Boyer, M, Brambila, R, Bray, B, Brennan, D, Briesemeister, A, Bringuier, S, Brookman, M, Brower, D, Brown, B, Brown, W, Buchenauer, D, Burke, M, Burrell, K, Butt, J, Buttery, R, Bykov, I, Candy, J, Canik, J, Cao, N, Carbajal Gomez, L, Carlson, L, Carlstrom, T, Carter, T, Cary, W, Casali, L, Cengher, M, Chan, V, Chen, B, Chen, J, Chen, M, Chen, R, Chen, X, Choi, W, Chrobak, C, Chrystal, C, Churchill, R, Cianciosa, M, Clauser, C, Clement, M, Coburn, J, Collins, C, Cooper, A, Covele, B, Crippen, J, Crocker, N, Crowley, B, Dal Molin, A, Davis, E, Degrassie, J, del-Castillo-Negrete, C, Delgado-Aparicio, L, Diallo, A, Diem, S, Ding, R, Ding, S, Ding, W, Doane, J, Donovan, D, Drake, J, Du, D, Du, H, Du, X, Duarte, V, Duran, J, Eidietis, N, Elder, D, Eldon, D, Elwasif, W, Ely, T, Eng, K, Engelhorn, K, Ennis, D, Erickson, K, Ernst, D, Evans, T, Fenstermacher, M, Ferraro, N, Ferron, J, Finkenthal, D, Fisher, P, Fishler, B, Flanagan, S, Fooks, J, Frassinetti, L, Frerichs, H, Fu, Y, Fulop, T, Gao, Q, Garcia, F, Garofalo, A, Gattuso, A, Giacomelli, L, Giraldez, E, Giroud, C, Glass, F, Gohil, P, Gong, X, Gorelov, Y, Granetz, R, Green, D, Greenfield, C, Grierson, B, Groebner, R, Grosnickle, W, Groth, M, Grunloh, H, Guo, H, Guo, W, Guterl, J, Hager, R, Hahn, S, Halpern, F, Han, H, Hansink, M, Hanson, J, Harris, J, Haskey, S, Hatch, D, Heidbrink, W, Herfindal, J, Hill, D, Hill, M, Hinson, E, Holcomb, C, Holland, C, Holland, L, Hollmann, E, Holm, A, Hong, R, Hoppe, M, Houshmandyar, S, Howard, J, Howard, N, Hu, Q, Hu, W, Huang, H, Huang, J, Huang, Y, Hughes, G, Hughes, J, Humphreys, D, Hyatt, A, Ida, K, Igochine, V, In, Y, Inoue, S, Isayama, A, Isler, R, Izzo, V, Jackson, M, Jarvinen, A, Jeon, Y, Ji, H, Jian, X, Jimenez, R, Johnson, C, Joseph, I, Kaczala, D, Kaplan, D, Kates-Harbeck, J, Kellman, A, Kellman, D, Kessel, C, Khumthong, K, Kim, C, Kim, H, Kim, J, Kim, K, Kim, S, Kimura, W, King, J, Kirk, A, Kleijwegt, K, Knolker, M, Kohn, A, Kolemen, E, Kostuk, M, Kramer, G, Kress, P, Kriete, D, La Haye, R, Laggner, F, Lan, H, Lanctot, M, Lantsov, R, Lao, L, Lasnier, C, Lau, C, Law, K, Lawrence, D, Le, J, Lee, R, Lehnen, M, Leon, R, Leonard, A, Lesher, M, Leuer, J, Li, G, Li, K, Liao, K, Lin, Z, Liu, C, Liu, F, Liu, Y, Liu, Z, Loch, S, Logan, N, Lohr, J, Lore, J, Luce, T, Luhmann, N, Lunsford, R, Luo, C, Luo, Z, Lupin-Jimenez, L, Lvovskiy, A, Lyons, B, Ma, X, Maingi, R, Makowski, M, Mantica, P, Manuel, M, Margo, M, Marinoni, A, Marmar, E, Martin, W, Masline, R, Matsunaga, G, Mauzey, D, Mauzey, P, Mcclenaghan, J, Mckee, G, Mclean, A, Mclean, H, Meier, E, Meitner, S, Menard, J, Meneghini, O, Merlo, G, Meyer, W, Miller, D, Miller, W, Moeller, C, Montes, K, Morales, M, Mordijck, S, Moser, A, Moyer, R, Muller, S, Munaretto, S, Murakami, M, Murphy, C, Muscatello, C, Myers, C, Nagy, A, Navratil, G, Nazikian, R, Neff, A, Neiser, T, Nelson, A, Nguyen, P, Nguyen, R, Nichols, J, Nocente, M, Nygren, R, O'Neill, R, Odstrcil, T, Ohdachi, S, Okabayashi, M, Olofsson, E, Ono, M, Orlov, D, Osborne, T, Pablant, N, Pace, D, Paguio, R, Pajares Martinez, A, Pan, C, Pankin, A, Park, J, Park, Y, Parker, C, Parker, S, Parks, P, Pawley, C, Paz-Soldan, C, Peebles, W, Penaflor, B, Petrie, T, Petty, C, Peysson, Y, Pigarov, A, Piglowski, D, Pinsker, R, Piovesan, P, Piper, N, Pitts, R, Pizzo, J, Podesta, M, Poli, F, Ponce, D, Porkolab, M, Porter, G, Prater, R, Qian, J, Ra, O, Rafiq, T, Raman, R, Rand, C, Randall, G, Rauch, J, Rea, C, Reinke, M, Ren, J, Ren, Q, Ren, Y, Rhodes, T, Rice, J, Rognlien, T, Rost, J, Rowan, W, Rudakov, D, Salmi, A, Sammuli, B, Samuell, C, Sandorfi, A, Sang, C, Sauter, O, Schissel, D, Schmitz, L, Schmitz, O, Schuster, E, Scoville, J, Seltzman, A, Sfiligoi, I, Shafer, M, Shen, H, Shi, T, Shiraki, D, Si, H, Smith, D, Smith, S, Snipes, J, Snyder, P, Solano, E, Solomon, W, Sontag, A, Soukhanovskii, V, Spong, D, Stacey, W, Staebler, G, Stagner, L, Stahl, B, Stangeby, P, Stoltzfus-Dueck, T, Stotler, D, Strait, E, Su, D, Sugiyama, L, Sulyman, A, Sun, Y, Sung, C, Suttrop, W, Suzuki, Y, Svyatkovskiy, A, Sweeney, R, Taimourzadeh, S, Takechi, M, Tala, T, Tan, H, Tang, S, Tang, X, Taussig, D, Taylor, G, Taylor, N, Taylor, T, Teklu, A, Thomas, D, Thomas, M, Thome, K, Thorman, A, Tinguely, R, Tobias, B, Tooker, J, Torreblanca, H, Torrezan De Sousa, A, Trevisan, G, Truong, D, Turco, F, Turnbull, A, Unterberg, E, Vaezi, P, Vail, P, Van Zeeland, M, Velasco Enriquez, M, Venkatesh, M, Victor, B, Volpe, F, Wade, M, Walker, M, Wall, J, Wallace, G, Waltz, R, Wang, G, Wang, H, Wang, Y, Wang, Z, Wang, F, Ward, S, Watkins, J, Watkins, M, Wehner, W, Weiland, M, Weisberg, D, Welander, A, White, A, White, R, Whyte, D, Wijkamp, T, Wilcox, R, Wilks, T, Wilson, H, Wingen, A, Wolfe, E, Wu, M, Wu, W, Wukitch, S, Xia, T, Xiang, N, Xiao, B, Xie, R, Xu, G, Xu, H, Xu, X, Yan, Z, Yang, Q, Yang, X, Yoshida, M, Yu, G, Yu, J, Yu, M, Zamperini, S, Zeng, L, Zhao, B, Zhao, D, Zhao, H, Zhao, Y, Zhu, Y, and Zywicki, B
- Subjects
Physics ,Nuclear and High Energy Physics ,fusion ,model ,Tokamak ,DIII-D ,Divertor ,Mechanics ,Plasma ,Fusion power ,Dissipation ,Condensed Matter Physics ,01 natural sciences ,010305 fluids & plasmas ,law.invention ,Pedestal ,Heat flux ,law ,Physics::Plasma Physics ,0103 physical sciences ,010306 general physics ,tokamak ,plasma ,energy - Abstract
DIII-D research is addressing critical challenges in preparation for ITER and the next generation of fusion devices through focusing on plasma physics fundamentals that underpin key fusion goals, understanding the interaction of disparate core and boundary plasma physics, and developing integrated scenarios for achieving high performance fusion regimes. Fundamental investigations into fusion energy science find that anomalous dissipation of runaway electrons (RE) that arise following a disruption is likely due to interactions with RE-driven kinetic instabilities, some of which have been directly observed, opening a new avenue for RE energy dissipation using naturally excited waves. Dimensionless parameter scaling of intrinsic rotation and gyrokinetic simulations give a predicted ITER rotation profile with significant turbulence stabilization. Coherence imaging spectroscopy confirms near sonic flow throughout the divertor towards the target, which may account for the convection-dominated parallel heat flux. Core-boundary integration studies show that the small angle slot divertor achieves detachment at lower density and extends plasma cooling across the divertor target plate, which is essential for controlling heat flux and erosion. The Super H-mode regime has been extended to high plasma current (2.0 MA) and density to achieve very high pedestal pressures (~30 kPa) and stored energy (3.2 MJ) with H 98y2 ≈ 1.6–2.4. In scenario work, the ITER baseline Q = 10 scenario with zero injected torque is found to have a fusion gain metric independent of current between q 95 = 2.8–3.7, and a lower limit of pedestal rotation for RMP ELM suppression has been found. In the wide pedestal QH-mode regime that exhibits improved performance and no ELMs, the start-up counter torque has been eliminated so that the entire discharge uses ≈0 injected torque and the operating space is more ITER-relevant. Finally, the high- (⩽3.8) hybrid scenario has been extended to the high-density levels necessary for radiating divertor operation, achieving ~40% divertor heat flux reduction using either argon or neon with P tot up to 15 MW.
- Published
- 2019
- Full Text
- View/download PDF
228. 582: In vivo nanoparticle-mediated therapeutic nucleic acid delivery for CF treatment.
- Author
-
Piotrowski-Daspit, A., Bracaglia, L., Barone, C., Nguyen, R., Glazer, P., Egan, M., and Saltzman, W.
- Subjects
- *
NUCLEIC acids - Published
- 2021
- Full Text
- View/download PDF
229. ePS5.01 CyFi Space: a smartphone application to support social connectedness and well-being in young people living with cystic fibrosis.
- Author
-
Francis, J., Cross, D., Schultz, A., Armstrong, D., Nguyen, R., and Branch-Smith, C.
- Subjects
- *
YOUTH , *QUALITY of life , *SOCIAL belonging , *CYSTIC fibrosis , *MOBILE apps - Published
- 2019
- Full Text
- View/download PDF
230. First and second trimester urinary metabolic profiles and fetal growth restriction: an exploratory nested case-control study within the infant development and environment study.
- Author
-
Luthra, Gauri, Vuckovic, Ivan, Bangdiwala, A., Gray, H., Redmon, J. B., Barrett, E. S., Sathyanarayana, S., Nguyen, R. H. N., Swan, S. H., Zhang, S., Dzeja, P., Macura, S. I., and Nair, K. S.
- Subjects
- *
FETAL development , *INFANT development , *BIOLOGICAL tags , *GESTATIONAL age , *NUCLEAR magnetic resonance spectroscopy - Abstract
Background: Routine prenatal care fails to identify a large proportion of women at risk of fetal growth restriction (FGR). Metabolomics, the comprehensive analysis of low molecular weight molecules (metabolites) in biological samples, can provide new and earlier biomarkers of prenatal health. Recent research has suggested possible predictive first trimester urine metabolites correlating to fetal growth restriction in the third trimester. Our objective in this current study was to examine urinary metabolic profiles in the first and second trimester of pregnancy in relation to third trimester FGR in a US population from a large, multi-center cohort study of healthy pregnant women.Methods: We conducted a nested case-control study within The Infant Development and the Environment Study (TIDES), a population-based multi-center pregnancy cohort study. We identified 53 cases of FGR based on the AUDIPOG [Neonatal growth - AUDIPOG [Internet]. [cited 29 Nov 2016]. Available from: http://www.audipog.net/courbes_morpho.php?langue=en ] formula for birthweight percentile considering maternal height, age, and prenatal weight, as well as infant sex, gestational age, and birth rank. Cases were matched to 106 controls based on study site, maternal age (± 2 years), parity, and infant sex. NMR spectroscopy was used to assess concentrations of four urinary metabolites that have been previously associated with FGR (tyrosine, acetate, formate, and trimethylamine) in first and second trimester urine samples. We fit multivariate conditional logistic regression models to estimate the odds of FGR in relation to urinary concentrations of these individual metabolites in the first and second trimesters. Exploratory analyses of custom binned spectroscopy results were run to consider other potentially related metabolites.Results: We found no significant association between the relative concentrations of each of the four metabolites and odds of FGR. Exploratory analyses did not reveal any significant differences in urinary metabolic profiles. Compared with controls, cases delivered earlier (38.6 vs 39.8, p < 0.001), and had lower birthweights (2527 g vs 3471 g, p < 0.001). Maternal BMI was similar between cases and controls.Conclusions: First and second trimester concentrations of urinary metabolites (acetate, formate, trimethylamine and tyrosine) did not predict FGR. This inconsistency with previous studies highlights the need for more rigorous investigation and data collection in this area before metabolomics can be clinically applied to obstetrics. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
231. Evaluating radiation transport errors in merger simulations using a Monte Carlo algorithm.
- Author
-
Foucart, F., Duez, M. D., Kidder, L. E., Nguyen, R., Pfeiffer, H. P., and Scheel, M. A.
- Subjects
- *
MONTE Carlo method , *NEUTRINOS , *NEUTRON stars - Abstract
Neutrino-matter interactions play an important role in the postmerger evolution of neutron star-neutron star and black hole-neutron star mergers. Most notably, they determine the properties of the bright optical/infrared transients observable after a merger. Unfortunately, Boltzmann's equations of radiation transport remain too costly to be evolved directly in merger simulations. Simulations rely instead on approximate transport algorithms with unquantified modeling errors. In this paper, we use for the first time a time-dependent general relativistic Monte Carlo (MC) algorithm to solve Boltzmann's equations and estimate important properties of the neutrino distribution function ∼10 ms after a neutron star merger that resulted in the formation of a massive neutron star surrounded by an accretion disk. We do not fully couple the MC algorithm to the fluid evolution, but use a short evolution of the merger remnant to critically assess errors in our approximate gray two-moment transport scheme. We demonstrate that the analytical closure used by the moment scheme is highly inaccurate in the polar regions, but performs well elsewhere. While the average energy of polar neutrinos is reasonably well captured by the two-moment scheme, estimates for the neutrino energy become less accurate at lower latitudes. The two-moment formalism also overestimates the density of neutrinos in the polar regions by ∼50%, and underestimates the neutrino pair-annihilation rate at the poles by factors of 2-3. Although the latter is significantly more accurate than one might have expected before this study, our results indicate that predictions for the properties of polar outflows and for the creation of a baryon-free region at the poles are likely to be affected by errors in the two-moment scheme, thus limiting our ability to reliably model kilonovae and gamma-ray bursts. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
232. Ion-implanted high-microwave-power indium phosphide transistors
- Author
-
Nguyen, R
- Published
- 1989
233. Phenolic content and antioxidant activity of Croatian and German honey.
- Author
-
Bok VV, Šola I, Rusak G, Budisavljević A, Nguyen R, Ludwig-Müller J, and Maleš Ž
- Abstract
Since honey has a therapeutic role in the treatment of many diseases, we investigated the content of phenolic compounds and the antioxidant activity in acacia ( Robinia pseudoacacia L.), chestnut ( Castanea sativa Mill.) and lime-tree ( Tilia spp.) honey originating from Croatia and Germany. Total phenols, flavonols, and flavanols contents were observed at higher levels in Croatian Castanea honey compared to German Castanea honey. Significant higher values of total flavanols and hydroxycinnamic acids were measured in Croatian Tilia honey compared to German Tilia honey. For Robinia honey, significantly higher values of total phenols and flavonols were observed in almost all Croatian honey samples compared to German honey. Croatian honey samples had higher antioxidant activity compared to German honey samples with most tested methods. The highest total phenols, total flavanols, ABTS, DPPH, and FRAP values were measured in Castanea honey, then in Robinia honey, and the lowest values in Tilia honey samples. With new developed HPLC method, pinobanksin, pinocembrin, and chrysin were identified in the majority of honey samples. Our results imply that both botanical and geographical origin influence the final quality of phenolic compounds and antioxidant activity in honey. A high positive correlation between the results of antioxidant activity and polyphenols was detected., (© 2024 Valerija Vujčić Bok et al., published by Sciendo.)
- Published
- 2024
- Full Text
- View/download PDF
234. Hippocampal contextualization of social rewards in mice.
- Author
-
Duarte JM, Nguyen R, Kyprou M, Li K, Milentijevic A, Cerquetella C, Forro T, and Ciocchi S
- Subjects
- Animals, Male, Mice, Mice, Inbred C57BL, Locus Coeruleus physiology, Fear physiology, Social Behavior, Cues, Reward, Hippocampus physiology, Optogenetics, Memory physiology, Neurons physiology
- Abstract
Acquiring and exploiting memories of rewarding experiences is critical for survival. The spatial environment in which a rewarding stimulus is encountered regulates memory retrieval. The ventral hippocampus (vH) has been implicated in contextual memories involving rewarding stimuli such as food, social cues or drugs. Yet, the neuronal representations and circuits underlying contextual memories of socially rewarding stimuli are poorly understood. Here, using in vivo electrophysiological recordings, in vivo one-photon calcium imaging, and optogenetics during a social reward contextual conditioning paradigm in male mice, we show that vH neurons discriminate between contexts with neutral or acquired social reward value. The formation of context-discriminating vH neurons following learning was contingent upon the presence of unconditioned stimuli. Moreover, vH neurons showed distinct contextual representations during the retrieval of social reward compared to fear contextual memories. Finally, optogenetic inhibition of locus coeruleus (LC) projections in the vH selectively disrupted social reward contextual memory by impairing vH contextual representations. Collectively, our findings reveal that the vH integrates contextual and social reward information, with memory encoding of these representations supported by input from the LC., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
235. Ocular manifestations of juvenile Sjögren's disease.
- Author
-
Nguyen R, Gomez-Castillo L, and Gonzales JA
- Subjects
- Humans, Child, Keratoconjunctivitis Sicca diagnosis, Keratoconjunctivitis Sicca etiology, Sjogren's Syndrome diagnosis, Sjogren's Syndrome complications
- Abstract
Purpose of Review: This review aims to enhance understanding of juvenile Sjögren's disease (jSjD) by exploring diagnostic criteria, ocular clinical features, ancillary ophthalmic testing, and management strategies specific to this rare pediatric condition., Recent Findings: Unlike adults, children with jSjD often present with recurrent parotitis and extra-glandular symptoms before developing sicca symptoms. Adult SjD classification criteria do not consider pediatric-specific symptoms and physiological differences. Underutilization of diagnostic tests such as the ocular staining score (OSS) and Schirmer I may result in an incomplete understanding of the prevalence of keratoconjunctivitis sicca in jSjD., Summary: Timely referral to an ophthalmologist can address perceived feasibility issues with respect to ocular features in jSjD. Management of keratoconjunctivitis sicca in jSjD includes improving ocular surface lubrication and decreasing inflammation. Recognition of pediatric-specific clinical features and development of universally accepted jSjD classification criteria will allow for better identification of potential participants for future jSjD studies., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
236. A wrap-around movement path randomization method to distinguish social and spatial drivers of animal interactions.
- Author
-
Gahm K, Nguyen R, Acácio M, Anglister N, Vaadia G, Spiegel O, and Pinter-Wollman N
- Subjects
- Animals, Falconiformes physiology, Behavior, Animal physiology, Models, Biological, Movement, Social Behavior
- Abstract
Studying the spatial-social interface requires tools that distinguish between social and spatial drivers of interactions. Testing hypotheses about the factors determining animal interactions often involves comparing observed interactions with reference or 'null' models. One approach to accounting for spatial drivers of social interactions in reference models is randomizing animal movement paths to decouple spatial and social phenotypes while maintaining environmental effects on movements. Here, we update a reference model that detects social attraction above the effect of spatial constraints. We explore the use of our 'wrap-around' method and compare its performance to the previous approach using agent-based simulations. The wrap-around method provides reference models that are more similar to the original tracking data, while still distinguishing between social and spatial drivers. Furthermore, the wrap-around approach results in fewer false-positives than its predecessor, especially when animals do not return to one place each night but change movement foci, either locally or directionally. Finally, we show that interactions among GPS-tracked griffon vultures ( Gyps fulvus ) emerge from social attraction rather than from spatial constraints on their movements. We conclude by highlighting the biological situations in which the updated method might be most suitable for testing hypotheses about the underlying causes of social interactions. This article is part of the theme issue 'The spatial-social interface: a theoretical and empirical integration'.
- Published
- 2024
- Full Text
- View/download PDF
237. Identification of DLK1, a Notch ligand, as an immunotherapeutic target and regulator of tumor cell plasticity and chemoresistance in adrenocortical carcinoma.
- Author
-
Sun NY, Kumar S, Kim YS, Varghese D, Mendoza A, Nguyen R, Okada R, Reilly K, Widemann B, Pommier Y, Elloumi F, Dhall A, Patel M, Aber E, Contreras-Burrola C, Kaplan R, Martinez D, Pogoriler J, Hamilton AK, Diskin SJ, Maris JM, Robey RW, Gottesman MM, Rivero JD, and Roper N
- Abstract
Immunotherapeutic targeting of cell surface proteins is an increasingly effective cancer therapy. However, given the limited number of current targets, the identification of new surface proteins, particularly those with biological importance, is critical. Here, we uncover delta-like non-canonical Notch ligand 1 (DLK1) as a cell surface protein with limited normal tissue expression and high expression in multiple refractory adult metastatic cancers including small cell lung cancer (SCLC) and adrenocortical carcinoma (ACC), a rare cancer with few effective therapies. In ACC, ADCT-701, a DLK1 targeting antibody-drug conjugate (ADC), shows potent in vitro activity among established cell lines and a new cohort of patient-derived organoids as well as robust in vivo anti-tumor responses in cell line-derived and patient-derived xenografts. However, ADCT-701 efficacy is overall limited in ACC due to high expression and activity of the drug efflux protein ABCB1 (MDR1, P-glycoprotein). In contrast, ADCT-701 is extremely potent and induces complete responses in DLK1
+ ACC and SCLC in vivo models with low or no ABCB1 expression. Genetic deletion of DLK1 in ACC dramatically downregulates ABCB1 and increases ADC payload and chemotherapy sensitivity through NOTCH1-mediated adrenocortical de-differentiation. Single cell RNA-seq of ACC metastatic tumors reveals significantly decreased adrenocortical differentiation in DLK low or negative cells compared to DLK1 positive cells. This works identifies DLK1 as a novel immunotherapeutic target that regulates tumor cell plasticity and chemoresistance in ACC. Our data support targeting DLK1 with an ADC in ACC and neuroendocrine neoplasms in an active first-in-human phase I clinical trial (NCT06041516)., Competing Interests: Nitin Roper and Jaydira Del Rivero have received research funding from ADC Therapeutics for this study. The other authors have no competing interests to report.- Published
- 2024
- Full Text
- View/download PDF
238. Exploring the Corrosion Potential of Three Bio-Based Furan Derivatives on Mild Steel in Aqueous HCl Solution: An Experimental Inquiry Enhanced by Theoretical Analysis.
- Author
-
Balkard B, Nguyen R, Mellaoui MD, Imjjad A, Oukhrib R, Len C, and Zejli H
- Abstract
This research deals with the corrosion inhibition of mild steel in a highly corrosive aqueous HCl medium with a concentration of 0.5 M, using three different corrosion inhibitors: furan-2-carboxylic acid ( 1 ), furan-2,5-dicarboxylic acid ( 2 ), and furan-2,5-diyldimethanol ( 3 ). Various electrochemical tests, such as potentiodynamic polarization (PP or Tafel curve) and electrochemical impedance spectroscopy, were systematically performed. The experimental results underscore the remarkable corrosion mitigating properties of inhibitors 1 - 3 on mild steel, showing inhibition efficiencies of 97.6, 99.5, and 95.8%, respectively, at a concentration of 5 × 10
-3 M and temperature T = 298 K. Notably, the inhibition efficiency of each inhibitor 1-3 shows a positive correlation with its concentration. In addition, consistent results from all electrochemical methods confirm that 1-3 act as mixed inhibitors. These findings remain robust across different experimental techniques, ensuring the reliability and comprehensiveness of the results. Theoretically, the inhibitors were optimized using the Density Functional Theory/B3LYP/6-311++G(d,p) method in gas and aqueous phase to evaluate their reactivity and stability. Among them, compound 2 stands out for its enhanced reactivity and stability, highlighted by optimal EHOMO and ELUMO values. Negative electrostatic potential mapping suggests potential reaction centers, while Fukui functions reveal localized sites of reactivity, supported by a favorable electronic distribution and specific interactions with metal surfaces. Reduced density gradient analysis also confirms the suitability of this compound for noncovalent interactions, in agreement with experimental data.These theoretical results are in good agreement with experimental data, confirming the excellent performance of compound 2 as a corrosion inhibitor., Competing Interests: The authors declare no competing financial interest., (© 2024 The Authors. Published by American Chemical Society.)- Published
- 2024
- Full Text
- View/download PDF
239. Targeting SWI/SNF ATPases reduces neuroblastoma cell plasticity.
- Author
-
Xu M, Hong JJ, Zhang X, Sun M, Liu X, Kang J, Stack H, Fang W, Lei H, Lacoste X, Okada R, Jung R, Nguyen R, Shern JF, Thiele CJ, and Liu Z
- Subjects
- Humans, Cell Line, Tumor, Cell Proliferation, Gene Expression Regulation, Neoplastic, DNA Helicases metabolism, DNA Helicases genetics, Chromatin Assembly and Disassembly, Chromosomal Proteins, Non-Histone metabolism, Chromosomal Proteins, Non-Histone genetics, Drug Resistance, Neoplasm genetics, Animals, Nuclear Proteins, Neuroblastoma genetics, Neuroblastoma pathology, Neuroblastoma metabolism, Cell Plasticity, Transcription Factors metabolism, Transcription Factors genetics
- Abstract
Tumor cell heterogeneity defines therapy responsiveness in neuroblastoma (NB), a cancer derived from neural crest cells. NB consists of two primary subtypes: adrenergic and mesenchymal. Adrenergic traits predominate in NB tumors, while mesenchymal features becomes enriched post-chemotherapy or after relapse. The interconversion between these subtypes contributes to NB lineage plasticity, but the underlying mechanisms driving this phenotypic switching remain unclear. Here, we demonstrate that SWI/SNF chromatin remodeling complex ATPases are essential in establishing an mesenchymal gene-permissive chromatin state in adrenergic-type NB, facilitating lineage plasticity. Targeting SWI/SNF ATPases with SMARCA2/4 dual degraders effectively inhibits NB cell proliferation, invasion, and notably, cellular plasticity, thereby preventing chemotherapy resistance. Mechanistically, depletion of SWI/SNF ATPases compacts cis-regulatory elements, diminishes enhancer activity, and displaces core transcription factors (MYCN, HAND2, PHOX2B, and GATA3) from DNA, thereby suppressing transcriptional programs associated with plasticity. These findings underscore the pivotal role of SWI/SNF ATPases in driving intrinsic plasticity and therapy resistance in neuroblastoma, highlighting an epigenetic target for combinational treatments in this cancer., (© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)
- Published
- 2024
- Full Text
- View/download PDF
240. Improved resilience and proteostasis mediate longevity upon DAF-2 degradation in old age.
- Author
-
Molière A, Park JYC, Goyala A, Vayndorf EM, Zhang B, Hsiung KC, Jung Y, Kwon S, Statzer C, Meyer D, Nguyen R, Chadwick J, Thompson MA, Schumacher B, Lee SV, Essmann CL, MacArthur MR, Kaeberlein M, David D, Gems D, and Ewald CY
- Subjects
- Animals, Insulin-Like Growth Factor I metabolism, Insulin metabolism, Caenorhabditis elegans, Longevity physiology, Proteostasis physiology, Caenorhabditis elegans Proteins metabolism, Caenorhabditis elegans Proteins genetics, Receptor, Insulin metabolism, Aging physiology, Aging metabolism, Signal Transduction physiology
- Abstract
Little is known about the possibility of reversing age-related biological changes when they have already occurred. To explore this, we have characterized the effects of reducing insulin/IGF-1 signaling (IIS) during old age. Reduction of IIS throughout life slows age-related decline in diverse species, most strikingly in the nematode Caenorhabditis elegans. Here we show that even at advanced ages, auxin-induced degradation of DAF-2 in single tissues, including neurons and the intestine, is still able to markedly increase C. elegans lifespan. We describe how reversibility varies among senescent changes. While senescent pathologies that develop in mid-life were not reversed, there was a rejuvenation of the proteostasis network, manifesting as a restoration of the capacity to eliminate otherwise intractable protein aggregates that accumulate with age. Moreover, resistance to several stressors was restored. These results support several new conclusions. (1) Loss of resilience is not solely a consequence of pathologies that develop in earlier life. (2) Restoration of proteostasis and resilience by inhibiting IIS is a plausible cause of the increase in lifespan. And (3), most interestingly, some aspects of the age-related transition from resilience to frailty can be reversed to a certain extent. This raises the possibility that the effect of IIS and related pathways on resilience and frailty during aging in higher animals might possess some degree of reversibility., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
241. Systemic in utero gene editing as a treatment for cystic fibrosis.
- Author
-
Ricciardi AS, Barone C, Putman R, Quijano E, Gupta A, Nguyen R, Mandl H, Piotrowski-Daspit AS, Lopez-Giraldez F, Luks V, Freedman-Weiss MR, Farrelly J, Ahle S, Glazer PM, Saltzman WM, Stitelman DH, and Egan ME
- Abstract
In utero gene editing has the potential to modify disease causing genes in multiple developing tissues before birth, possibly allowing for normal organ development, disease improvement, and conceivably, cure. In cystic fibrosis (CF), a disease that arises from mutations in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene, there are signs of multiorgan disease affecting the function of the respiratory, gastrointestinal, and reproductive systems already present at birth. Thus, treating CF patients early is crucial for preventing or delaying irreversible organ damage. Here we demonstrate proof-of-concept of multiorgan mutation correction in CF using peptide nucleic acids (PNAs) encapsulated in polymeric nanoparticles and delivered systemically in utero. In utero editing was associated with sustained postnatal CFTR activity, at a level similar to that of wild-type mice, in both respiratory and gastrointestinal tissue, without detection of off-target mutations in partially homologous loci. This work suggests that systemic in utero gene editing represents a viable strategy for treating monogenic diseases before birth that impact multiple tissue types.
- Published
- 2024
- Full Text
- View/download PDF
242. The impact of socioeconomic determinants on the access to care and survival in patients with spinal chordomas- a national cancer database analysis.
- Author
-
Battistin U, Nguyen R, Ghaith AK, El-Hajj VG, Soltan F, Ghaith S, Weinberg JH, Elmi-Terander A, Grossbach AJ, and Akinduro OO
- Subjects
- Humans, Female, Middle Aged, Male, Healthcare Disparities statistics & numerical data, Aged, Survival Rate, United States epidemiology, Adult, Prognosis, Chordoma mortality, Chordoma therapy, Chordoma surgery, Health Services Accessibility statistics & numerical data, Socioeconomic Factors, Databases, Factual, Spinal Neoplasms mortality, Spinal Neoplasms therapy, Spinal Neoplasms surgery
- Abstract
Purpose: Chordomas are rare malignant neoplasms primarily treated surgically. Disparities related to race and socioeconomic status, may affect patient outcomes. This study aims to identify prognostic factors for access to care and survival in patients with spinal chordomas., Methods: The NCDB database was queried between the years 2004 and 2017. Kaplan-Meier curves were constructed to compare survival probabilities among different groups, based on race and socioeconomic determinents., Results: 1769 patients were identified, with 87% being White, 5% Hispanic, 4% Black, and Asian each. The mean age was 61.3 years. Most patients received care at academic/research centers and lived in a large metropolitan area, with no difference between races. A significantly higher percentage of Black patients did not undergo surgery (p < 0.001), with no statistically significant difference in survival between races (p = 0.97). A higher survival probability was seen in patients with other government insurances (p < 0.0001), in higher income quartiles (p < 0.0001), in metropolitan areas (p = 0.023), and at an academic/research center (p < 0.0001). A lower survival probability was seen in patients who are uninsured, in rural areas, and at community cancer programs (p < 0.0001)., Conclusion: This study highlights disparities in access to surgical intervention for patients with spinal chordomas, especially among Black individuals. It emphasizes the significant impact of insurance status and income on access to surgical care and highlights geographical and institutional variations in survival rates. Addressing socioeconomic differences is crucial for fostering equity in neurosurgical outcomes., (© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
243. CAR T-cells for pediatric solid tumors: where to go from here?
- Author
-
Trautmann T, Yakobian N, and Nguyen R
- Subjects
- Humans, Child, Tumor Microenvironment immunology, Animals, Receptors, Antigen, T-Cell immunology, Neoplasms immunology, Neoplasms therapy, Neoplasms pathology, Immunotherapy, Adoptive methods, Receptors, Chimeric Antigen immunology, T-Lymphocytes immunology
- Abstract
Despite the great success that chimeric antigen receptor (CAR) T-cells have had in patients with B-cell malignancies and multiple myeloma, they continue to have limited efficacy against most solid tumors. Especially in the pediatric population, pre- and post-treatment biopsies are rarely performed due to ethical reasons, and thus, our understanding is still very limited regarding the mechanisms in the tumor microenvironment by which tumor cells exclude effectors and attract immune-suppressive cells. Nevertheless, based on the principles that are known, current T-cell engineering has leveraged some of these processes and created more potent CAR T-cells. The recent discovery of new oncofetal antigens and progress made in CAR design have expanded the potential pool of candidate antigens for therapeutic development. The most promising approaches to enhance CAR T-cells are novel CAR gating strategies, creative ways of cytokine delivery to the TME without enhancing systemic toxicity, and hijacking the chemokine axis of tumors for migratory purposes. With these new modifications, the next step in the era of CAR T-cell development will be the clinical validation of these promising preclinical findings., Competing Interests: Declarations Ethical approval N/A. Informed consent N/A Competing interests R.N. filed a patent (WO2023158986A1) for GPC2-CARs., (© 2024. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.)
- Published
- 2024
- Full Text
- View/download PDF
244. Perioperative Outcomes and Reimbursement Patterns Associated With the Anterior versus Posterior Approach for Treatment of Type 2 Odontoid Fractures, a National Surgical Quality Improvement Program Analysis.
- Author
-
El-Hajj VG, Ghaith AK, Al-Saidi NN, Nguyen R, Habashy KJ, and Elmi-Terander A
- Abstract
Objective: To evaluate the short-term surgical outcomes and the reimbursement patterns, after treatment of type 2 odontoid fractures using the anterior or posterior approach., Methods: The National Surgical Quality Improvement Program database was queried for surgically treated patients with type 2 odontoid fractures by the anterior or posterior approach between 2016 and 2020. Propensity score matching with the optimal approach was used to balance the cohorts., Results: A total of 96 patients in the anterior and 352 patients in the posterior surgery group were included in the unmatched analysis. After propensity score matching 1:1, 96 anterior and 96 posterior cases were included in the matched analysis. Operative times were shorter in the anterior group (92.0 vs. 145.0 minutes, P < 0.001). The need for intraoperative or postoperative transfusions was higher in the posterior group (15% vs. 2.1%; P = 0.002). However, there were no significant differences in complications between groups (P > 0.05). Hospital stay was significantly longer in the posterior group (4.5 days vs. 3.0; P = 0.049). Nonroutine discharge was more frequent in the posterior group (55% vs. 40%, P = 0.030). However, the rate of 30-day readmission, reoperation, and mortality did not differ between groups (P > 0.05). Also, the work relative value units were significantly higher in the anterior group (22.7 vs. 20.6, P < 0.001), indicating higher reimbursement trends for this approach., Conclusions: In this matched analysis, the anterior approach for type 2 odontoid fractures was superior to the posterior approach. The anterior approach was associated with significantly shorter operation times, hospital stays, fewer transfusions, nonroutine discharges, and higher reimbursements., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
245. Minimally invasive posterior cervical foraminotomy versus the anterior transcorporeal approach for cervical radiculopathy: a systematic review and meta-analysis.
- Author
-
Rajjoub R, Nguyen R, Ghaith AK, El-Hajj VG, De Biase G, Onyedimma C, Yolcu YU, Jarrah R, Elmi-Terander A, Akinduro OO, Abode-Iyamah K, and Bydon M
- Subjects
- Humans, Decompression, Surgical methods, Treatment Outcome, Radiculopathy surgery, Foraminotomy methods, Cervical Vertebrae surgery, Minimally Invasive Surgical Procedures methods
- Abstract
Objective: Surgical decompression is often indicated for symptomatic cases of cervical radiculopathy. In the cervical spine, minimally invasive posterior cervical foraminotomy (MIS-PCF) and the anterior transcorporeal approach (ATCA) are modern techniques available to surgeons. This systematic review and single-arm meta-analysis aimed to assess surgical and patient-reported outcomes of MIS-PCF and ATCA for cervical radiculopathy., Methods: A systematic review of the literature was conducted using 1) Ovid; 2) Epub Ahead of Print and In-Process, In-Data-Review & Other Non-Indexed Citations; and 3) Scopus databases, which reported outcomes following cervical decompression using MIS-PCF or the ATCA. Specifically, baseline characteristics, operative outcomes, and changes in visual analog scale (VAS) neck pain score were assessed. The quality of the studies was graded using the modified Newcastle-Ottawa Scale for observational studies., Results: Forty studies with 1661 patients were identified. The comparative analysis of both techniques revealed no significant differences in complication (7%, 95% CI 5%-10%, p = 0.75) or reoperation rates (5%, 95% CI 3%-7%, p = 0.41). Additionally, there were no significant differences in estimated blood loss (55.39, 95% CI 44.62-66.16 ml, p = 0.55) or operative time (85.15, 95% CI 65.38-104.92 minutes, p = 0.05). The ATCA showed significantly greater improvement (p < 0.01) in VAS neck pain scores following surgery (ATCA point reduction 6.7, 95% CI 6.0-7.5 points vs MIS-PCF 3.0, 95% CI 1.0-5.0 points)., Conclusions: The ATCA and MIS-PCF are effective modern techniques for the surgical treatment of radiculopathy. Both approaches showed comparable postoperative outcomes, including complication and reoperation rates. However, the ATCA was shown to provide significantly greater improvement in VAS neck pain scores.
- Published
- 2024
- Full Text
- View/download PDF
246. Electrochemical Probing of Human Liver Subcellular S9 Fractions for Drug Metabolite Synthesis.
- Author
-
Medina D, Omanakuttan B, Nguyen R, Alwarsh E, and Walgama C
- Abstract
Human liver subcellular fractions, including liver microsomes (HLM), liver cytosol fractions, and S9 fractions, are extensively utilized in in vitro assays to predict liver metabolism. The S9 fractions are supernatants of human liver homogenates that contain both microsomes and cytosol, which include most cytochrome P450 (CYP) enzymes and soluble phase II enzymes such as glucuronosyltransferases and sulfotransferases. This study reports on the direct electrochemistry and biocatalytic features of redox-active enzymes in S9 fractions for the first time. We investigated the electrochemical properties of S9 films by immobilizing them onto a high-purity graphite (HPG) electrode and performing cyclic voltammetry under anaerobic (Ar-saturated) and aerobic (O
2 -saturated) conditions. The heterogeneous electron transfer rate between the S9 film and the HPG electrode was found to be 14 ± 3 s-1 , with a formal potential of -0.451 V vs. Ag/AgCl reference electrode, which confirmed the electrochemical activation of the FAD/FMN cofactor containing CYP450-reductase (CPR) as the electron receiver from the electrode. The S9 films have also demonstrated catalytic oxygen reduction under aerobic conditions, identical to HLM films attached to similar electrodes. Additionally, we investigated CYP activity in the S9 biofilm for phase I metabolism using diclofenac hydroxylation as a probe reaction and identified metabolic products using liquid chromatography-mass spectrometry (LC-MS). Investigating the feasibility of utilizing liver S9 fractions in such electrochemical assays offers significant advantages for pharmacological and toxicological evaluations of new drugs in development while providing valuable insights for the development of efficient biosensor and bioreactor platforms.- Published
- 2024
- Full Text
- View/download PDF
247. Challenges and opportunities in neurosurgical care transition.
- Author
-
Lohkamp LN, Nguyen R, and Greenfield JP
- Subjects
- Humans, Neurosurgery trends, Neurosurgical Procedures methods, Neurosurgical Procedures trends
- Published
- 2024
- Full Text
- View/download PDF
248. Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications.
- Author
-
Safri F, Nguyen R, Zerehpooshnesfchi S, George J, and Qiao L
- Subjects
- Humans, Genetic Heterogeneity, Animals, Carcinoma, Hepatocellular therapy, Carcinoma, Hepatocellular genetics, Carcinoma, Hepatocellular pathology, Carcinoma, Hepatocellular metabolism, Liver Neoplasms therapy, Liver Neoplasms pathology, Liver Neoplasms genetics, Liver Neoplasms metabolism
- Abstract
Hepatocellular Carcinoma (HCC) is one of the most common types of primary liver cancer. Current treatment options have limited efficacy against this malignancy, primarily owing to difficulties in early detection and the inherent resistance to existing drugs. Tumor heterogeneity is a pivotal factor contributing significantly to treatment resistance and recurrent manifestations of HCC. Intratumoral heterogeneity is an important aspect of the spectrum of complex tumor heterogeneity and contributes to late diagnosis and treatment failure. Therefore, it is crucial to thoroughly understand the molecular mechanisms of how tumor heterogeneity develops. This review aims to summarize the possible molecular dimensions of tumor heterogeneity with an emphasis on intratumoral heterogeneity, evaluate its profound impact on the diagnosis and therapeutic strategies for HCC, and explore the suitability of appropriate pre-clinical models that can be used to best study tumor heterogeneity; thus, opening new avenues for cancer treatment., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
249. Development of a Novel Mobile Health App to Empower Young People With Type 1 Diabetes to Exercise Safely: Co-Design Approach.
- Author
-
Shetty VB, Fried L, Roby HC, Soon WHK, Nguyen R, Ong A, Jaimangal M, Francis J, Paramalingam N, Cross D, and Davis E
- Abstract
Background: Blood glucose management around exercise is challenging for youth with type 1 diabetes (T1D). Previous research has indicated interventions including decision-support aids to better support youth to effectively contextualize blood glucose results and take appropriate action to optimize glucose levels during and after exercise. Mobile health (mHealth) apps help deliver health behavior interventions to youth with T1D, given the use of technology for glucose monitoring, insulin dosing, and carbohydrate counting., Objective: We aimed to develop a novel prototype mHealth app to support exercise management among youth with T1D, detail the application of a co-design process and design thinking principles to inform app design and development, and identify app content and functionality that youth with T1D need to meet their physical activity goals., Methods: A co-design approach with a user-centered design thinking framework was used to develop a prototype mHealth app "acT1ve" during the 18-month design process (March 2018 to September 2019). To better understand and respond to the challenges among youth with diabetes when physically active, 10 focus groups were conducted with youth aged 13-25 years with T1D and parents of youth with T1D. Thereafter, we conducted participatory design workshops with youth to identify key app features that would support individual needs when physically active. These features were incorporated into a wireframe, which was critically reviewed by participants. A beta version of "acT1ve" was built in iOS and android operating systems, which underwent critical review by end users, clinicians, researchers, experts in exercise and T1D, and app designers., Results: Sixty youth with T1D, 14 parents, 6 researchers, and 10 clinicians were engaged in the development of "acT1ve." acT1ve included key features identified by youth, which would support their individual needs when physically active. It provided advice on carbohydrates and insulin during exercise, information on hypoglycemia treatment, pre- and postexercise advice, and an educational food guide regarding exercise management. "acT1ve" contained an exercise advisor algorithm comprising 240 pathways developed by experts in diabetes and exercise research. Based on participant input during exercise, acT1ve provided personalized insulin and carbohydrate advice for exercise lasting up to 60 minutes. It also contains other features including an activity log, which displays a complete record of the end users' activities and associated exercise advice provided by the app's algorithm for later reference, and regular reminder notifications for end users to check or monitor their glucose levels., Conclusions: The co-design approach and the practical application of the user-centered design thinking framework were successfully applied in developing "acT1ve." The design thinking processes allowed youth with T1D to identify app features that would support them to be physically active, and particularly enabled the delivery of individualized advice. Furthermore, app development has been described in detail to help guide others embarking on a similar project., Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12619001414101; https://tinyurl.com/mu9jvn2d., (©Vinutha B Shetty, Leanne Fried, Heather C Roby, Wayne H K Soon, Rebecca Nguyen, Arthur Ong, Mohinder Jaimangal, Jacinta Francis, Nirubasini Paramalingam, Donna Cross, Elizabeth Davis. Originally published in JMIR Diabetes (https://diabetes.jmir.org), 30.07.2024.)
- Published
- 2024
- Full Text
- View/download PDF
250. Fingertip amputations in children: Atasoy flap's indications and limitations.
- Author
-
Nguyen R, Delvaque JG, Mas V, Ilharreborde B, and Jehanno P
- Abstract
Introduction: The Atasoy flap is considered simple and reliable for covering distal digital defects in adults. Various studies in children have shown more contrasting results, particularly in terms of aesthetics and function. The aim of this study is to evaluate the long-term results of this flap specifically in children, in order to determine its limitations and indications., Hypothesis: The Atasoy flap is reliable and reproducible for coverage of distal digital substance loss up to zone 2 in children., Materials and Methods: Fifty-six children who benefited from an Atasoy flap operated on between January 2017 and January 2020 were included. Lesion area, operative technique, postoperative complications (infection, healing difficulties, necrosis), and ultimately nail appearance, cold intolerance or finger pain, finger eviction, extension defect, and final parental satisfaction were analyzed., Results: Forty-nine children were evaluated with a mean follow-up of 18 months (min = 3 months, max = 38 months, SD = 11.3 months). Eighteen children had a hook nail, resulting in 6 of them having their finger excluded. The majority of hook nails were found in zone III and in proximal zone II lesions (12 cases). Eighty-nine percent of children with distal suture fixation to the nail bed (8 children) had this complication. Cold intolerance was present in 9 children. There were no cases of extension failure or early post-operative complications. Final parent satisfaction was 9.1/10 (min = 5, max = 10, SD = 1.3)., Conclusion: The Atasoy flap in children appears reliable for covering loss of distal digital substance. The main complication is the occurrence of hook nails. Compliance with its indications (transverse substance loss not exceeding the proximal third of zone II) and a precise surgical technique (distal needle fixation without suturing to the nail bed, deep flap lift, non-closure of the donor site) help limit this risk., Level of Evidence: IV; retrospective study., (Copyright © 2024. Published by Elsevier Masson SAS.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.